JPH0429671B2 - - Google Patents
Info
- Publication number
- JPH0429671B2 JPH0429671B2 JP58183243A JP18324383A JPH0429671B2 JP H0429671 B2 JPH0429671 B2 JP H0429671B2 JP 58183243 A JP58183243 A JP 58183243A JP 18324383 A JP18324383 A JP 18324383A JP H0429671 B2 JPH0429671 B2 JP H0429671B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- thio
- furfuryl
- dimethylamino
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 80
- -1 cyclopropylene amine Chemical class 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 208000025865 Ulcer Diseases 0.000 claims abstract description 10
- 231100000397 ulcer Toxicity 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 44
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 44
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 37
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 35
- 239000011541 reaction mixture Substances 0.000 claims description 21
- NXGHEDHQXXXTTP-UHFFFAOYSA-N 1,1-bis(methylsulfanyl)-2-nitroethene Chemical group CSC(SC)=C[N+]([O-])=O NXGHEDHQXXXTTP-UHFFFAOYSA-N 0.000 claims description 20
- 229910021529 ammonia Inorganic materials 0.000 claims description 17
- JKRUSMLUQVGEAP-UHFFFAOYSA-N n,n-dimethyl-1-[5-(2-methylsulfanylethylsulfanylmethyl)furan-2-yl]methanamine Chemical compound CSCCSCC1=CC=C(CN(C)C)O1 JKRUSMLUQVGEAP-UHFFFAOYSA-N 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 238000009938 salting Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- IGTWYMQBGKAFCF-UHFFFAOYSA-N 1-(2-nitroethenyl)piperidine Chemical compound [O-][N+](=O)C=CN1CCCCC1 IGTWYMQBGKAFCF-UHFFFAOYSA-N 0.000 claims 1
- ODHRVQTXERBFCH-UHFFFAOYSA-N 1-n'-cyclopentyl-1-n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-2-nitroethene-1,1-diamine Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=C[N+]([O-])=O)NC1CCCC1 ODHRVQTXERBFCH-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 abstract description 4
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 abstract description 3
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical group CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 abstract description 2
- VXVVUHQULXCUPF-UHFFFAOYSA-N cycloheptanamine Chemical compound NC1CCCCCC1 VXVVUHQULXCUPF-UHFFFAOYSA-N 0.000 abstract description 2
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 abstract description 2
- 150000001412 amines Chemical class 0.000 abstract 3
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 125000004341 endo-2-norbornyl group Chemical group [H]C1([H])C([H])([H])[C@@]2([H])C([H])([H])[C@]1([H])C([H])([H])[C@@]2([H])* 0.000 abstract 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 abstract 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 description 59
- 230000015572 biosynthetic process Effects 0.000 description 57
- 238000002844 melting Methods 0.000 description 37
- 230000008018 melting Effects 0.000 description 37
- 238000001816 cooling Methods 0.000 description 20
- 238000000921 elemental analysis Methods 0.000 description 20
- 238000002798 spectrophotometry method Methods 0.000 description 20
- 241000700159 Rattus Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 10
- BSGRLBPZSRZQOR-UHFFFAOYSA-N ethene-1,1-diamine Chemical compound NC(N)=C BSGRLBPZSRZQOR-UHFFFAOYSA-N 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 229960001380 cimetidine Drugs 0.000 description 7
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 7
- RPMXALUWKZHYOV-UHFFFAOYSA-N nitroethene Chemical compound [O-][N+](=O)C=C RPMXALUWKZHYOV-UHFFFAOYSA-N 0.000 description 7
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 7
- 229960000620 ranitidine Drugs 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 108010012944 Tetragastrin Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 4
- ZERULLAPCVRMCO-UHFFFAOYSA-N sulfure de di n-propyle Natural products CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 description 4
- RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010020601 Hyperchlorhydria Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 231100001048 fetal toxicity Toxicity 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- KYWOXJAUDNZQRA-UHFFFAOYSA-N 1-morpholin-4-yl-2-nitroethenamine Chemical compound [O-][N+](=O)C=C(N)N1CCOCC1 KYWOXJAUDNZQRA-UHFFFAOYSA-N 0.000 description 2
- IJCPGHIDEIVIBY-UHFFFAOYSA-N 1-n'-cycloheptyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(N)NC1CCCCCC1 IJCPGHIDEIVIBY-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- JKLNYGDWYRKFKR-UHFFFAOYSA-N ethyl methyl sulfate Chemical compound CCOS(=O)(=O)OC JKLNYGDWYRKFKR-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000007666 subchronic toxicity Effects 0.000 description 2
- 231100000195 subchronic toxicity Toxicity 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RZUDRRXSEJRTQY-UHFFFAOYSA-N 1-(4-methylpiperidin-1-yl)-2-nitroethenamine Chemical compound CC1CCN(C(N)=C[N+]([O-])=O)CC1 RZUDRRXSEJRTQY-UHFFFAOYSA-N 0.000 description 1
- WAKUKXKZEXFXJP-UHFFFAOYSA-N 1-ethylpiperidin-3-amine Chemical compound CCN1CCCC(N)C1 WAKUKXKZEXFXJP-UHFFFAOYSA-N 0.000 description 1
- SJAYVOJJODYDIC-UHFFFAOYSA-N 1-n'-(1-cyclohexa-1,4-dien-1-ylethyl)-1-n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-2-nitroethene-1,1-diamine Chemical compound C=1CC=CCC=1C(C)NC(=C[N+]([O-])=O)NCCSCC1=CC=C(CN(C)C)O1 SJAYVOJJODYDIC-UHFFFAOYSA-N 0.000 description 1
- YKBXCFKSXRIETQ-UHFFFAOYSA-N 1-n'-(1-cyclohexa-1,4-dien-1-ylethyl)-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(N)NC(C)C1=CCC=CC1 YKBXCFKSXRIETQ-UHFFFAOYSA-N 0.000 description 1
- PNPUEIWCJJPATO-UHFFFAOYSA-N 1-n'-cyclohexyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(N)NC1CCCCC1 PNPUEIWCJJPATO-UHFFFAOYSA-N 0.000 description 1
- MSYBMQREJYVMHZ-UHFFFAOYSA-N 1-n'-cyclopentyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(N)NC1CCCC1 MSYBMQREJYVMHZ-UHFFFAOYSA-N 0.000 description 1
- MODJSVSYMDTXMX-UHFFFAOYSA-N 2-(4-ethenylpiperazin-1-yl)ethanol Chemical compound C1N(CCN(C1)CCO)C=C MODJSVSYMDTXMX-UHFFFAOYSA-N 0.000 description 1
- XKBGOFIASRVHAR-UHFFFAOYSA-N 2-[4-(1-amino-2-nitroethenyl)piperazin-1-yl]ethanol Chemical compound [O-][N+](=O)C=C(N)N1CCN(CCO)CC1 XKBGOFIASRVHAR-UHFFFAOYSA-N 0.000 description 1
- DNINUKCIPWSQMA-UHFFFAOYSA-N 2-nitro-1-piperidin-1-ylethenamine Chemical compound [O-][N+](=O)C=C(N)N1CCCCC1 DNINUKCIPWSQMA-UHFFFAOYSA-N 0.000 description 1
- XJMNCSRHVMDXNL-UHFFFAOYSA-N 2-nitro-1-pyrrolidin-1-ylethenamine Chemical compound [O-][N+](=O)C=C(N)N1CCCC1 XJMNCSRHVMDXNL-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- UGBKOURNNQREPE-UHFFFAOYSA-N azepan-1-amine Chemical compound NN1CCCCCC1 UGBKOURNNQREPE-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VUGPBMNWZGYRDX-UHFFFAOYSA-N n-ethylcyclohexa-1,4-dien-1-amine Chemical compound CCNC1=CCC=CC1 VUGPBMNWZGYRDX-UHFFFAOYSA-N 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
- C07D203/12—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
æ¬çºæã¯æ朰ç掻æ§ãæããæ°èŠååç©ããã®
補æ³ãåã³ããããå«ãè¬ç©çµæç©ã«é¢ãããæŽ
ã«è©³ããã¯ãåŒïŒïŒïŒ ãåŒäžãã¯ãããªãžããïŒâã¡ãã«ãããªãž
ããïŒïŒââãšãã«ãããªãžãã«ïŒã¢ãããïŒ
âïŒïŒâããããã·ãšãã«ïŒâïŒâããã©ãžããïŒ
âãã³ãžã«ãããªãžããïŒâãã³ãžã«ããã©ãž
ãããšãã¬ã³ã€ãããã·ã¯ããããã¬ã³ã€ããã
ã·ã¯ãããã·ã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãž
ãšãã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãžãšãã«â
ïŒâã¡ãã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãžãšã
ã«âïŒâãšãã«ã¢ããããããµã¡ãã¬ã³ã€ããã
ïŒïŒ®âãããµã¡ãã¬ã³ã€ããïŒã¢ãããã·ã¯ãã
ããã«ã¢ããããããªãžããã¢ã«ããªãããšã³ã
âïŒâãã«ãã«ãã«ã¢ããåã¯ãã«ãã«ãã³âïŒ
âã€ã«ã¢ããåºãè¡šãããã ã§ç€ºãããååç©åã³ãããã®è¬ç©çã«èš±å®¹ãåŸ
ãå¡©ã«é¢ããã ããã§è¬ç©çã«èš±å®¹ãããå¡©ã¯ãäŸãã°å¡©åæ°Ž
çŽ å¡©ãèåæ°ŽçŽ å¡©ããšãŠåæ°ŽçŽ é žããªã³é žãåã¯
ç¡«é žçã®ç¡æ©é žãå ããŠåŸãç¡æ¯æ§ã®å¡©ãåã³ã
ã¬ã€ã³é žããªã³ãŽé žãé ¢é žãã¯ãšã³é žãããã
é žããã¯ãé žãå®æ¯éŠé žå¡©ãé ç³é žãããã«é žã
ããã«é žããã³ãã«é žãã¢ã¹ã³ã«ãã³é žãã¡ãã«
ã¹ã«ãã³é žåã¯ãšãã«ã¹ã«ãã³é žçã®ææ©é žãå
ããŠåŸãç¡æ¯æ§ã®å¡©ãããªãã æ¬çºæã¯ãåèšåŒïŒïŒã®ååç©åã¯ãã®è¬ç©
çã«èš±å®¹ãåŸãå¡©ã®æ°èŠãªè£œé æ¹æ³ã«ãé¢ããã
ãã¯ã åŒïŒïŒïŒ ã§ç€ºãããïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã
ãšã åŒïŒïŒïŒ ãåŒäžãã¯åè¿°ã®æå³ãæãããã ã§ç€ºãããååç©ãšã80âã§åå¿ãããããã
åŸãåŸãããååç©ãåé¢ããæŽã«å¿ èŠã«ããå¡©
åããããšãç¹åŸŽãšãããã®ã§ããã 以äžã«èª¬æããåŒïŒïŒã®ååç©åã³ãããã®
è¬ç©çã«èš±å®¹ãããå¡©ã¯ãæ¶ååšå®ã®æœ°çãã¢ã¬
ã«ã®ãŒæ§ç®èçç¶çã®ãã¹ã¿ãã³H2å容äœã«å¯Ÿ
ããæ®æç©è³ªã®æäžãèŠããçŸæ£ã®æ²»çã«æçšã§
ããããšã蚌æãããŠããããã®æ§ã«ãæ¬çºæã¯
è¬ç©çµæç©ã«ãé¢ããããã¯æŽ»æ§èŠçŽ ãšããŠåŒ
ïŒïŒã®ååç©åã³ãããã®è¬ç©çã«èš±å®¹ããã
å¡©ã®ïŒçš®åã¯ïŒçš®ä»¥äžãå«æãããã®ãŸãŸããã
ããã¯è¬å¹ãæããå ¬ç¥ååç©ã§ãã€ãŠäžèšåŒ
ïŒïŒã®ååç©ãšæ··å䜵çšããŠãé害ãåŒãèµ·ã
ãååŠå€åãçžäºæ®æäœçšã瀺ãããšã®ãªãåå
ç©ãåã³ïŒåã¯è³Šåœ¢å€ãåžéå€ã溶å€åã³ïŒåã¯
è¬ç©çã«èš±å®¹ãããå¢éå€ãšçµåãããã®ã§ãã
ããšãç¹åŸŽãšãããã®ã§ããã è¡šïŒã¯ïŒ²ã®æå³ãšå ±ã«ãã®ã·ã³ãã«ãä»ããŠåŒ
ïŒïŒã®ååç©ã®å ·äœäŸã瀺ãããã®ã§ããã
補æ³ãåã³ããããå«ãè¬ç©çµæç©ã«é¢ãããæŽ
ã«è©³ããã¯ãåŒïŒïŒïŒ ãåŒäžãã¯ãããªãžããïŒâã¡ãã«ãããªãž
ããïŒïŒââãšãã«ãããªãžãã«ïŒã¢ãããïŒ
âïŒïŒâããããã·ãšãã«ïŒâïŒâããã©ãžããïŒ
âãã³ãžã«ãããªãžããïŒâãã³ãžã«ããã©ãž
ãããšãã¬ã³ã€ãããã·ã¯ããããã¬ã³ã€ããã
ã·ã¯ãããã·ã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãž
ãšãã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãžãšãã«â
ïŒâã¡ãã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãžãšã
ã«âïŒâãšãã«ã¢ããããããµã¡ãã¬ã³ã€ããã
ïŒïŒ®âãããµã¡ãã¬ã³ã€ããïŒã¢ãããã·ã¯ãã
ããã«ã¢ããããããªãžããã¢ã«ããªãããšã³ã
âïŒâãã«ãã«ãã«ã¢ããåã¯ãã«ãã«ãã³âïŒ
âã€ã«ã¢ããåºãè¡šãããã ã§ç€ºãããååç©åã³ãããã®è¬ç©çã«èš±å®¹ãåŸ
ãå¡©ã«é¢ããã ããã§è¬ç©çã«èš±å®¹ãããå¡©ã¯ãäŸãã°å¡©åæ°Ž
çŽ å¡©ãèåæ°ŽçŽ å¡©ããšãŠåæ°ŽçŽ é žããªã³é žãåã¯
ç¡«é žçã®ç¡æ©é žãå ããŠåŸãç¡æ¯æ§ã®å¡©ãåã³ã
ã¬ã€ã³é žããªã³ãŽé žãé ¢é žãã¯ãšã³é žãããã
é žããã¯ãé žãå®æ¯éŠé žå¡©ãé ç³é žãããã«é žã
ããã«é žããã³ãã«é žãã¢ã¹ã³ã«ãã³é žãã¡ãã«
ã¹ã«ãã³é žåã¯ãšãã«ã¹ã«ãã³é žçã®ææ©é žãå
ããŠåŸãç¡æ¯æ§ã®å¡©ãããªãã æ¬çºæã¯ãåèšåŒïŒïŒã®ååç©åã¯ãã®è¬ç©
çã«èš±å®¹ãåŸãå¡©ã®æ°èŠãªè£œé æ¹æ³ã«ãé¢ããã
ãã¯ã åŒïŒïŒïŒ ã§ç€ºãããïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã
ãšã åŒïŒïŒïŒ ãåŒäžãã¯åè¿°ã®æå³ãæãããã ã§ç€ºãããååç©ãšã80âã§åå¿ãããããã
åŸãåŸãããååç©ãåé¢ããæŽã«å¿ èŠã«ããå¡©
åããããšãç¹åŸŽãšãããã®ã§ããã 以äžã«èª¬æããåŒïŒïŒã®ååç©åã³ãããã®
è¬ç©çã«èš±å®¹ãããå¡©ã¯ãæ¶ååšå®ã®æœ°çãã¢ã¬
ã«ã®ãŒæ§ç®èçç¶çã®ãã¹ã¿ãã³H2å容äœã«å¯Ÿ
ããæ®æç©è³ªã®æäžãèŠããçŸæ£ã®æ²»çã«æçšã§
ããããšã蚌æãããŠããããã®æ§ã«ãæ¬çºæã¯
è¬ç©çµæç©ã«ãé¢ããããã¯æŽ»æ§èŠçŽ ãšããŠåŒ
ïŒïŒã®ååç©åã³ãããã®è¬ç©çã«èš±å®¹ããã
å¡©ã®ïŒçš®åã¯ïŒçš®ä»¥äžãå«æãããã®ãŸãŸããã
ããã¯è¬å¹ãæããå ¬ç¥ååç©ã§ãã€ãŠäžèšåŒ
ïŒïŒã®ååç©ãšæ··å䜵çšããŠãé害ãåŒãèµ·ã
ãååŠå€åãçžäºæ®æäœçšã瀺ãããšã®ãªãåå
ç©ãåã³ïŒåã¯è³Šåœ¢å€ãåžéå€ã溶å€åã³ïŒåã¯
è¬ç©çã«èš±å®¹ãããå¢éå€ãšçµåãããã®ã§ãã
ããšãç¹åŸŽãšãããã®ã§ããã è¡šïŒã¯ïŒ²ã®æå³ãšå ±ã«ãã®ã·ã³ãã«ãä»ããŠåŒ
ïŒïŒã®ååç©ã®å ·äœäŸã瀺ãããã®ã§ããã
ãè¡šã

CHïŒâCHïŒâCHïŒ
CHïŒâCHïŒâCHïŒ
ãè¡šã
åŒïŒïŒã®ååç©çŸ€åã³ãããã®è¬ç©çã«èš±å®¹
ããã塩矀ã¯ããã¹ã¿ãã³H2ã®å容äœæäžãèŠ
ããæ¶åæ§æœ°çåã³ã¢ã¬ã«ã®ãŒæ§ç®èçç¶çã®çœ¹
æ£ã®æ²»çã«æŽ»æ§ãæãããäŸãã°ãæ朰ç掻æ§ã«
ã€ããŠã¯ãåœæ¥è ã«æ¢ç¥ã®æŽ»æ§èŠçŽ ã§ããã©ãã
ãžã³åã¯ã·ã¡ããžã³ããã®ã掻æ§ãæããŠããã
詳ããã¯ãåŒïŒïŒã®ååç©çŸ€åã³ãã®å¡©çŸ€ã¯ã©
ãããžã³ã®1.1ã1.3åãã·ã¡ããžã³ã®ïŒã10åã®
掻æ§ãæããå®éã«å¯äœçšãå¥ããªããšããå¹æ
ãããããã®æ§ãªé«æŽ»æ§åã³å¯äœçšã®éååšã«é¢
ããŠã¯ãæ¥æ§æ¯æ§ãäºæ ¢æ§æ¯æ§ãæ ¢æ§æ¯æ§ãèå
æ¯æ§ãåã³å¹œéçµçŽ®åã³è²¯çãèåæ³ç©ã¯ãã³ã«
ããã©ã¬ã¹ããªã³ã«ç±æ¥ããèé žéå€ã«é¢ããç
究ã«ãã€ãŠæ¢ã«ç¢ºèªãããŠããã æ¥æ§æ¯æ§ã«ã€ããŠã¯ãã¹ã€ã¹æ ªã®éåã³éããŠ
ã¹åã³ãŠã€ã¹ã¿ãŒæ ªã®éåã³éçœåã©ããã«æŽ»æ§
èŠçŽ ãçµå£ãéèå 泚å°ãçè泚å°ã®è«žæäžãæœ
ããŠæ€æ»ãããŠãããåæäžæ¹æ³ã«ãããŠã幟äœ
çŽæ°çæäžéã§åç©10äœã芳å¯æé10æ¥ã§æäžã
è¡ãªãããã芳å¯æéã®çµäºæç¹ã§ãLD50ãšçž
å¯Ÿä¿¡é Œé床ãšããªãããã€ãŒã«ãåã³ãŠã€ã«ã³ã¯
ãœã³ïŒãã¢ãŒãã³ã«ããšã¯ã¹ãïŒã»ã©ã»ã96â
191949ïŒãLitchfield and WilcoxonïŒPharmacol.
Exp.Ther.ã96â191949ïŒãã®æ¹æ³ã«ãã€ãŠèšç®
ããããçµæãè¡šïŒã«ç€ºããã
ããã塩矀ã¯ããã¹ã¿ãã³H2ã®å容äœæäžãèŠ
ããæ¶åæ§æœ°çåã³ã¢ã¬ã«ã®ãŒæ§ç®èçç¶çã®çœ¹
æ£ã®æ²»çã«æŽ»æ§ãæãããäŸãã°ãæ朰ç掻æ§ã«
ã€ããŠã¯ãåœæ¥è ã«æ¢ç¥ã®æŽ»æ§èŠçŽ ã§ããã©ãã
ãžã³åã¯ã·ã¡ããžã³ããã®ã掻æ§ãæããŠããã
詳ããã¯ãåŒïŒïŒã®ååç©çŸ€åã³ãã®å¡©çŸ€ã¯ã©
ãããžã³ã®1.1ã1.3åãã·ã¡ããžã³ã®ïŒã10åã®
掻æ§ãæããå®éã«å¯äœçšãå¥ããªããšããå¹æ
ãããããã®æ§ãªé«æŽ»æ§åã³å¯äœçšã®éååšã«é¢
ããŠã¯ãæ¥æ§æ¯æ§ãäºæ ¢æ§æ¯æ§ãæ ¢æ§æ¯æ§ãèå
æ¯æ§ãåã³å¹œéçµçŽ®åã³è²¯çãèåæ³ç©ã¯ãã³ã«
ããã©ã¬ã¹ããªã³ã«ç±æ¥ããèé žéå€ã«é¢ããç
究ã«ãã€ãŠæ¢ã«ç¢ºèªãããŠããã æ¥æ§æ¯æ§ã«ã€ããŠã¯ãã¹ã€ã¹æ ªã®éåã³éããŠ
ã¹åã³ãŠã€ã¹ã¿ãŒæ ªã®éåã³éçœåã©ããã«æŽ»æ§
èŠçŽ ãçµå£ãéèå 泚å°ãçè泚å°ã®è«žæäžãæœ
ããŠæ€æ»ãããŠãããåæäžæ¹æ³ã«ãããŠã幟äœ
çŽæ°çæäžéã§åç©10äœã芳å¯æé10æ¥ã§æäžã
è¡ãªãããã芳å¯æéã®çµäºæç¹ã§ãLD50ãšçž
å¯Ÿä¿¡é Œé床ãšããªãããã€ãŒã«ãåã³ãŠã€ã«ã³ã¯
ãœã³ïŒãã¢ãŒãã³ã«ããšã¯ã¹ãïŒã»ã©ã»ã96â
191949ïŒãLitchfield and WilcoxonïŒPharmacol.
Exp.Ther.ã96â191949ïŒãã®æ¹æ³ã«ãã€ãŠèšç®
ããããçµæãè¡šïŒã«ç€ºããã
ãè¡šã
ãè¡šã
äºæ
¢æ§æ¯æ§éšã¯å被詊éšååç©ãå¹³åäœé120
ã°ã©ã ã®çœåã©ãããã¹ãã©ã°ã»ããŒãªãŒæ ª
ïŒSprague Dawley stockïŒãéåã³éå50äœã
100äœã«ã€ããŠè¡ãªããããæšæºç°å¢åã³é£é€ç¶
æ³ã®ã©ããã¯å25äœã®ïŒã°ã«ãŒãã«åå²ãããã
ãããã«ã€ããŠè¡šïŒã«ç€ºããæäžéã§éèå 泚å°
ïŒæ²»çæéïŒé±éã§æ¯æ¥é±ïŒåã®å²åïŒã§æäžã
è¡ãªãããã
ã°ã©ã ã®çœåã©ãããã¹ãã©ã°ã»ããŒãªãŒæ ª
ïŒSprague Dawley stockïŒãéåã³éå50äœã
100äœã«ã€ããŠè¡ãªããããæšæºç°å¢åã³é£é€ç¶
æ³ã®ã©ããã¯å25äœã®ïŒã°ã«ãŒãã«åå²ãããã
ãããã«ã€ããŠè¡šïŒã«ç€ºããæäžéã§éèå 泚å°
ïŒæ²»çæéïŒé±éã§æ¯æ¥é±ïŒåã®å²åïŒã§æäžã
è¡ãªãããã
ãè¡šã
äžèšå被éšååç©ã«ã€ããŠã¯ãç¬10äœãå³ã¡çŽ
10Kgéã®ããŒã°ã«è¡çµ±ã®æç¬éïŒäœãéïŒäœã«ã€
ããŠãè©Šéšãè¡ãªããããæšæºç°å¢åã³é£é€ç¶æ³
ã®ç¬ã¯åïŒäœã®ïŒã°ã«ãŒãã«åå²ãããã第ïŒã°
ã«ãŒãïŒã³ã³ãããŒã«ïŒã¯åé±ïŒåã§ïŒé±ã«ãã
ã€ãŠçç溶液ãæäžããã第ïŒã°ã«ãŒãã¯ååç©
矀AUïŒ001â002â003â004â005â006â007â
008â009â010â011â012â013â014â015â016
â017â018â019â020ãæäžéïŒmgïŒKgã§åæ§ã«
åé±ïŒåã§ïŒé±ã«ããã€ãŠæäžããã ãããã®çµæãã³ã³ãããŒã«æ€äœåã³æ¬çºæå
åç©ã®æäžãåããæ€äœã®äœãã«ã€ããŠãã©ãã
åã³ç¬ã®äœèª¿ã¯åªè¯ã«ä¿æããããè¡æ¶²åŠçãè¡
液ååŠçãå°¿ãåã³è¡æ¶²ç çåŠçæ€æ»ã¯æ£åžžã®ç¯
å²å ã®å€ã瀺ãããäžèšæäžã«åž°ããã¹ãç°åžžã¯
äœãèµ·ãããªãã€ãã æ ¢æ§æ¯æ§è©Šéšã¯ãå被éšååç©ã«ã€ããŠåæ§
å¥ãå¹³åäœé97±ïŒã°ã©ã ã®ã¹ãã©ã°ã»ããŒãªãŒ
çš®ã®çœåã©ãã60äœãåã³åæ§å¥ãå¹³åäœé10Kg
ãããŒã°ã«ç¬10äœã«ã€ããŠè¡ãªãããããããã©
ããåã³ç¬ã«å¯Ÿããæäžã¯çµå£ïŒã©ããã«ã€ããŠ
ã¯èå ãããŒãïŒã§ãè¡šïŒã«ç€ºããAUïŒ001ã
ãAUïŒ020ã®åååç©ã«ã€ããŠè¡šïŒã«ç€ºããç
æäžéãåé±ïŒåã§24é±ã«ããã€ãŠæäžããã
10Kgéã®ããŒã°ã«è¡çµ±ã®æç¬éïŒäœãéïŒäœã«ã€
ããŠãè©Šéšãè¡ãªããããæšæºç°å¢åã³é£é€ç¶æ³
ã®ç¬ã¯åïŒäœã®ïŒã°ã«ãŒãã«åå²ãããã第ïŒã°
ã«ãŒãïŒã³ã³ãããŒã«ïŒã¯åé±ïŒåã§ïŒé±ã«ãã
ã€ãŠçç溶液ãæäžããã第ïŒã°ã«ãŒãã¯ååç©
矀AUïŒ001â002â003â004â005â006â007â
008â009â010â011â012â013â014â015â016
â017â018â019â020ãæäžéïŒmgïŒKgã§åæ§ã«
åé±ïŒåã§ïŒé±ã«ããã€ãŠæäžããã ãããã®çµæãã³ã³ãããŒã«æ€äœåã³æ¬çºæå
åç©ã®æäžãåããæ€äœã®äœãã«ã€ããŠãã©ãã
åã³ç¬ã®äœèª¿ã¯åªè¯ã«ä¿æããããè¡æ¶²åŠçãè¡
液ååŠçãå°¿ãåã³è¡æ¶²ç çåŠçæ€æ»ã¯æ£åžžã®ç¯
å²å ã®å€ã瀺ãããäžèšæäžã«åž°ããã¹ãç°åžžã¯
äœãèµ·ãããªãã€ãã æ ¢æ§æ¯æ§è©Šéšã¯ãå被éšååç©ã«ã€ããŠåæ§
å¥ãå¹³åäœé97±ïŒã°ã©ã ã®ã¹ãã©ã°ã»ããŒãªãŒ
çš®ã®çœåã©ãã60äœãåã³åæ§å¥ãå¹³åäœé10Kg
ãããŒã°ã«ç¬10äœã«ã€ããŠè¡ãªãããããããã©
ããåã³ç¬ã«å¯Ÿããæäžã¯çµå£ïŒã©ããã«ã€ããŠ
ã¯èå ãããŒãïŒã§ãè¡šïŒã«ç€ºããAUïŒ001ã
ãAUïŒ020ã®åååç©ã«ã€ããŠè¡šïŒã«ç€ºããç
æäžéãåé±ïŒåã§24é±ã«ããã€ãŠæäžããã
ãè¡šã
ãè¡šã
被éšååç©ã®ã©ããåã³ç¬ãžã®æ¯æ¥æäžã«ãã€
ãŠã¯è¡æ¶²åŠçãè¡æ¶²ååŠçãå°¿çŽ åã³ãã¯ããªã
ããã¯ãã¹ã³ãŒããã¯ãªäž»åšå®ã®æ æ§ã«äœãã®å€
åããããããªãã€ããäœéãã¿ãŒã³åã³æ»äº¡ç
ã«ã€ããŠå€åã¯çŸãããŠããªããæäžéã¯ãå®
éãäºå®ã®äººäœæ²»ççšéãããå€ããã®ã§ãã€
ãã èå æ¯æ§è©Šéšã¯ãã¹ãã©ã°ã»ããŒãªãŒçœåã©ã
ã100äœãé40äœãé60äœãå¹³åäœé125ã°ã©ã ã«
ã€ããŠè¡ãªããããåçš®éšååç©0.25ã50ã100
mgïŒKgã®éãé10äœã®åã°ã«ãŒãã«å¯ŸããŠèåå
60æ¥éã«çµå£æäžãããŸãé20äœã®åã°ã«ãŒãã«
察ããŠèåå15æ¥éã«ãããçµå£æäžããã å被éšååç©ã«ã€ããŠãããŠãŒãžãŒã©ã³ãã»ã
ã¯ã€ãæ ªã®ãŠãµã®æäœãå¹³åäœéïŒKgã40äœã«ã€
ããŠãè©Šéšãè¡ãªããããåååç©ã¯ïŒã20ã
40ã60mgïŒKgã®æäžéã§åä»»åŸïŒæ¥ç®ãã18æ¥ç®
ã«ãããŠçµå£æäžãããã èå æ¯æ§è©Šéšã®çµæã¯ãåŠåš ã®é²è¡åã³åèç©
質ã«å¯Ÿãè² ã®å¹²æžã瀺ããã®ã§ã¯ãªãã€ããæäž
éã¯ãå®éãäºå®ã®äººäœæ²»ççšéãããå€ããã®
ã§ãã€ããè¡šïŒã«ç€ºããAUïŒ010ããAUïŒ020
ãŸã§ã®å šãŠã®ååç©ã«ã€ããŠè©Šéšãè¡ãªãããã å¿è埪ç°å¹æã®è©äŸ¡ã¯ãå被éšååç©ã«ã€ã
ãŠãããŠãŒãžãŒã©ã³ãã»ãã¯ã€ãæ ªãå¹³åäœé
2.5Kgã®éãŠãµã®ïŒäœã«ã€ããŠè¡ãªããããæäž
ã«éãåãŠã¶ã®ã«éº»é ãæœããçµå£æäžã®å Žå
ïŒïŒäœïŒã¯100mgïŒKgãéè泚å°ã®å ŽåïŒïŒäœïŒ
ã¯ã20mgïŒKgã®æäžéãšããããã®çµæãåè
å§ãåŒåžæ¯å¹ åã³ã²ã床ãåã³å¿é»å³æ²ç·ã«äœã
ã®å€åããªãã€ããAUïŒ001ããAUïŒ020ãŸã§
ã®å šãŠã®ååç©ã«ã€ããŠè©Šéšãè¡ãªãããã æ¬çºæååç©ã®å¹æã調ã¹ããããã¹ãã©ã°ã»
ããŒãªãŒæ ªãå¹³åäœé200ã°ã©ã ã®éåã³éã©ã
ã50äœãäŸè©Šãããã é£é€äžã®ãããæ€äœã¯å¹œéçµçŽ®ã«äŸããããã
è¡åŸïŒæéããŠè¢«æ€ååç©ïŒã310ã30mgïŒKgã®
éãåã¯ã·ã¡ããžã³ïŒã10ã30ã100mgïŒKgãªã
ãã©ãããžã³ïŒãïŒã10ã30mgïŒKgã®éã§æäžã
è¡ãªãããã æ¬çºæååç©ãã·ã¡ããžã³åã³ã©ãããžã³ã®å š
ãŠã®æäžã«ã€ããŠå¹œéçµçŽ®ã«ããããããããè
朰çé»æ¢ã«ã€ããŠææã®çµæãäžããã æ¬çºæã«é¢ãã被æ€ååç©ã®æŽ»æ§ã¯ã·ã¡ããžã³
ã®çŽïŒåãã©ãããžã³ã®1.2ã1.3åã§ãã€ãã
AUïŒ001ããAUïŒ020ãŸã§å šãŠã®ååç©ã«ã€ã
ãŠèª¿ã¹ãããã 貯çã«åºã朰çã«å¯Ÿããæ¬çºæååç©ã®å¹æã
調ã¹ãããã«ã¹ãã©ã°ã»ããŒãªãŒæ ªãå¹³åäœéçŽ
200ã°ã©ã ã®çœåã©ããé60äœãäŸããããæ€äœ
ã®ïŒã€ã®ã°ã«ãŒãã¯è³Šåœ¢å€ã®ã¿ãäžãããã³ã³ã
ããŒã«æ€äœãšããŠæ±ããããïŒã€ã®æ€äœã°ã«ãŒã
ã¯ïŒåã³10mgïŒKgã®æäžéã§è¢«æ€ååç©ãçµå£æ
äžããŠååŠçãæœãããã貯ççšã±ãŒãžã«çœ®ãã
ãåã«ã·ã¡ããžã³10åã³20mgïŒKgã®çµå£æäžãå
ããïŒã€ã®æ€äœã°ã«ãŒããå ãããããæçµç
ã«ã貯ççšã±ãŒãžã«çœ®ãããåã«ã©ãããžã³ïŒå
ã³10mgïŒKgã®çµå£æäžãåããïŒã€ã®æ€äœã°ã«ãŒ
ããå ããããã å·é貯çã«ãã€ãŠå®éšçã«é»æ¢ãããè朰çé »
床ã¯ã3.3åéã®ã·ã¡ããžã³åã³1.1ã1.2åã®ã©ã
ããžã³æäžã«ãããŠèŠ³å¯ããããããé¡èãªçšåºŠ
ã«ãæ¬çºæååç©æäžã«ãããŠæžããããã
AUïŒ001ããAUïŒ020ãŸã§ã®å šãŠã®ååç©ã«ã€
ããŠè©Šéšãè¡ãªãããã æ¬çºæååç©ã®è²¯çã«åºã朰çã«å¯Ÿããæ²»çç
å¹æã調ã¹ããããã¹ãã©ã°ã»ããŒãªãŒæ ªãå¹³å
äœé200ã°ã©ã ã®éçœåã©ãã30äœãçšããããã
æ€äœã¯16æé絶é£ããã枩床21âã§24æéã«ãã
ã貯çã±ãŒãžã«å容ãããããããåŸã«éæŸã
ããæé·15æ¥éã«ããã€ãŠäžèšèŠé ã§ååç©ãæ
äžãããã 第ïŒã°ã«ãŒãïŒïŒæ¥åŸïŒïŒæ€äœïŒåã³15æ¥åŸïŒïŒ
æ€äœïŒã«äŸãããã³ã³ãããŒã«æ€äœ 第ïŒã°ã«ãŒãïŒïŒæ¥åŸïŒïŒæ€äœïŒåã³15æ¥åŸïŒïŒ
æ€äœïŒã«è¢«æ€ååç©2.5mgïŒKgãçµå£æäžãã
ãæ€äœ 第ïŒã°ã«ãŒãïŒïŒæ¥åŸïŒïŒæ€äœïŒåã³15æ¥åŸïŒïŒ
æ€äœïŒã«è¢«æ€ååç©ïŒmgïŒKgãçµå£æäžããã
æ€äœ 被æ€ååç©ã®ç¹°è¿ãæäžã¯è²¯çã«åºã朰çã®ç¢
çåãå©ãããAUïŒ001ããAUïŒ020ãŸã§ã®å š
ãŠã®ååç©ã«ã€ããŠè©Šéšãè¡ãªãããã ã¹ãã©ã°ã»ããŒãªãŒæ ªã®éçœåã©ããã«å¯Ÿã
0.25åã³0.50mgïŒKgã®çµå£æäžãåã³0.10åã³
0.20mgïŒKgã®éèå æäžãæœãããAUïŒ001ãã
AUïŒ020ãŸã§ã®æ¬çºæååç©ã¯ãèå åæ³ç©å
ã³èå é žåºŠãããªãã®éã§æå¶ããè液ã®PHãå€
åãããåå ãšããªããªãã€ãã ããã©ã¬ã¹ããªã³ã«åºãèé žéå€ã«å¯Ÿããæ¬çº
æååç©ã®å¹æã調ã¹ããããã¹ãã©ã°ã»ããŒãª
ãŒæ ªãå¹³åäœé180ã°ã©ã ã®éçœåã©ãã30äœã
äŸãããã 16æé絶é£ãããæ€äœã¯ãšãã«ãŠã¬ã¿ã³ãçšã
ãŠéº»é äžã«ããããã幜éåã³é£éé éšçµçŽ®ã®
åŸãæ€äœã®èäžã«ã«ããŠãŒã¬ãæ¿å ¥ããã€ã·ã€ã
ã·ãã©ãããžã€ããïŒãžãšãŒïŒãã¢ãŒãã³ã«ïŒ
18ã93â1968ïŒIshil and ShinorakiãJap.J.
Pharmacol.18ã93â1968ïŒã®æ¹æ³ã«åŸã€ãŠèå
åæ³ç©ãéããããããã®æ§ã«åŠçœ®ãããæ€äœã«
ç®äžæ³šå°ã«ãã0.5mgïŒKgã®ããã©ã¬ã¹ããªã³ã
æäžãããããã®æäžãšåæã«ãæ€äœã¯çç溶液
ïŒã³ã³ãããŒã«ïŒåã¯éè泚å°ã«ãã被æ€ååç©
0.25åã³0.5mgïŒKgã®æäžãæœãããã ããã©ã¬ã¹ããªã³æäžã«ããéé žåºŠã¯è¢«æ€åå
ç©ã®éèæäžã«ããããªãã®çšåºŠæå¶ãããã
AUïŒ001ããAUïŒ020ãŸã§ã®ååç©ãè©Šéšã«äŸ
ãããã åŒïŒïŒã®ååç©åã³ãããã®è¬ç©çã«èš±å®¹ã
ããå¡©ã¯ãé«æŽ»æ§ãæããå®è³ªçã«å¯äœçšãæã
ãªãããè¬ç©çµæç©ã®åœ¢æã«ãããŠæŽ»æ§èŠçŽ ãšã
ãŠç¹ã«æçšã§ããããããã€ãŠãæ¬çºæã¯ããã
ã®ååç©ã掻æ§èŠçŽ ãšããŠïŒçš®åã¯ïŒçš®ä»¥äžæå¹
éå«æããè¬ç©çµæç©ã«ãé¢ãããã®ã§ãããã
ã®ãŸãŸãããããã¯è¬å¹ãæããå ¬ç¥ååç©ã§ã
ã€ãŠäžèšåŒïŒïŒã®ååç©ãšæ··å䜵çšããŠãé害
ãåŒãèµ·ããååŠå€åãçžäºæ®æäœçšã瀺ãããš
ã®ãªãååç©ãåã³ïŒåã¯è³Šåœ¢å€ãåžéå€ã溶å€
åã³ïŒåã¯è¬ç©çã«èš±å®¹ãããå¢éå€ãšå ±ã«çšã
ãããã 該è¬ç©çµæç©ã¯ãçµå£ãçŽè žã泚å°åã¯å±éšæ
äžçšãšããŠèª¿è£œããããšãã§ãããäŸãã°ãã«ã
ã»ã«ãé å€ãæ¯éâæŸåºåé å€ãïŒåæäžåè¢
è©°ãåè¬ãè»éªšçã®åºåç¶ã溶液ãããã ã液ã
ä¹³å€çã®æ¶²ç¶ãšããããã®æ§ãªåœ¢æ åã¯å³æ調å
çšãšããŠçšãããããåèšè¬ç©çµæç©ã®å šãŠã¯ã
åžéå€ã賊圢å€ã溶å€åã³ïŒåã¯å¢éå€ãšããŠå ¬
ç¥ã®ãã®ãå«ãããã«èª¿è£œããããšãã§ããããŸ
ã調補æ¹æ³ãšããŠå ¬ç¥ã®æ¹æ³ãçšããããšãã§
ããäŸãã°ããã¯ãããžã¢ ãã¢ãŒãã·ãŠãŒãã€
ã«ãã·ã«ããã»ã«ãµãã€ãªâããã«ã»ããµã«ãã
ãŽãªã¢ã«ãã€ã«âãã©ã1972ïŒâTecnologia
FarmaceuticaâãSilvano CasadioâPubl.
Cisalpino ColiardicaâMilano1972ïŒã«ååã«èš
èŒãããŠããã æ¬çºæååç©ã¯ãã®ãŸãŸåã¯å¡©ã®åœ¢ã§ãïŒæ¥ã
ãã0.2ã50mgïŒKgã奜ãŸããã¯0.5ã2.0mgïŒKgã®
éã§æäžããããšãã§ããè¬éåŠçã«ãäŸãã°
10ã20ã30ã50ã100ã200ã250åã¯500mgã®éã§
ïŒæ¥ãããïŒãïŒåã«ãããŠæç¶çã«æäžããã®
ãæå©ã§ããã æ¬çºæã¯ããŸããåŒïŒïŒã®ååç©åã³ãã®è¬
ç©çã«èš±å®¹ãããå¡©ã®è£œé æ¹æ³ã«ãé¢ããŠããã
ãã®æ¹æ³ã¯åŒïŒïŒïŒ ã®ïŒâãããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ãâïŒâ
ãã©ãã«ãã¡ãã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€
ããåŒïŒïŒïŒ ïŒåŒäžãã¯åè¿°ã®æå³ãæãããïŒ ã®ååç©ãã枩床80âã§åå¿ããããããåŸãåŸ
ãããåŒïŒïŒã®ååç©ãåé¢ããå¿ èŠã«å¿ããŠ
å¡©åããããšã«ããå®æœãããã奜ãŸããã¯ãåŒ
ïŒïŒã®ååç©ãéå°é䜿çšãããåå¿ã¯ïŒæé
ç¶è¡ãããã åŒïŒïŒã®ååç©ã¯ãæ¬çºæã®ä»ã®äž»é¡ãæ§æ
ãã補é æ¹æ³ãå³ã¡ãåŒïŒïŒïŒ ã®ïŒïŒïŒãã¹ïŒã¡ãã«ããªïŒâïŒâããããšãã¬
ã³ãåŒïŒïŒïŒRHïŒïŒ²ã¯åè¿°ã®æå³ãæããïŒãš
åå¿ããã次ãã§ã¢ã³ã¢ãã¢ãšåå¿ãããæ¹æ³ã«
ãã€ãŠè£œé ããããšãã§ããããã®åå¿ã¯å®çšç
ã«ã¯ææ©æº¶åªäžã奜ãŸããã¯ããã©ã¯ãããšã¿ã³
äžã§è¡ãªããããåŸãããååç©ã®ç²Ÿè£œã¯ã·ãªã«
ã²ã«ã«ã©ã ééåã³åçµæ¶ã«ããè¡ãªãããã åŒïŒïŒã®ååç©ã¯ã€ã¿ãªã¢åœç¹èš±åºé¡
19473AïŒ82ïŒæ¬é¡ãšåäžåºé¡äººïŒã«èšèŒã®æ¹æ³ã«
ãã€ãŠèª¿è£œããããšãã§ããã åŸãããåŒïŒïŒã®ååç©ã¯åœæ¥è ã«å ¬ç¥ã®æ¹
æ³ã«ãã€ãŠå®¹æã«åé¢ããããšãã§ãããäŸãã°
溶åªããã®åçµæ¶ãªã©ãçšããããšãã§ããã奜
ãŸããã¯ãçšãã溶åªãšããŠæ°Žâãšãã«ã¢ã«ã³ãŒ
ã«æ··æ¶²ãæããããšãã§ããã å¿ èŠã«ããè¡ãªãããå¡©åã¯åœæ¥è ã«å ¬ç¥ã®æ¹
æ³ãäŸãã°é©å®ã®é žãå ããããšã«ãã€ãŠè¡ãªã
ããšãã§ããã 次ã«å®æœäŸã瀺ããŠæ¬çºæãæŽã«è©³ãã説æã
ãããæ¬çºæã®å®æœã®æ æ§ã¯ãããã«éå®ãããª
ãã å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒâ
ãããªãžãâïŒâããããšãã³ïŒAUïŒ001ïŒ
ã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ïŒããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ã®ïŒâã¢ããâïŒâãããªãžãâïŒâããããš
ãã³35ã°ã©ã ã80âã§ïŒæéåå¿ããããåå¿æ··
åç©ãå·åŽããšãã«ãšãŒãã«äžã«ãšãã次ãã§
éããæ²æŸ±ããšãã«ã¢ã«ã³ãŒã«ã«æº¶è§£ãå床氎äž
ã§æ²æŸ±ããããåŸãããæ²æŸ±ãæ°Žã»ãšãã«ã¢ã«ã³
ãŒã«æ··æ¶²ã§åçµæ¶ããããèç¹101â105âãåå
å 床枬å®ã«ããæ§é ãåå®ããããšãã§ããã å çŽ åæ C17H28N4O3S ååé 368.481     èšç®å€(%) 55.51 7.66 15.21 8.70 å®æž¬å€(%) 55.8 7.5 15.2 8.60 å®æœäŸ ïŒ ïŒâãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãã¢ããâïŒâïŒïŒ
âã¡ãã«ãããªãžãïŒâïŒâããããšãã³
ïŒAUïŒ002ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâïŒïŒâã¡ãã«ãããªãžãïŒâ
ïŒâããããšãã³37ã°ã©ã ã80âã§ïŒæéåå¿ã
ãããå·åŽåŸå®æœäŸïŒãšåäžåŠçãè¡ãªãããã
èç¹105â110âãåå å 床枬å®ã«ããæ§é ãåå®
ããããšãã§ããã å çŽ åæ C18H30N4O3S ååé 382.508     èšç®å€(%) 56.52 7.91 14.658.38 å®æž¬å€(%) 57 7.90 15 8.35 å®æœäŸ ïŒ ïŒ®âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒïŒ®âãšã
ã«ãããªãžãã«ïŒâïŒâãããâïŒïŒïŒâãšã
ã³ãžã¢ãã³ïŒAUïŒ003ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââïŒïŒ®âãšãã«ãããªãžãã«ïŒ
âïŒïŒïŒâãšãã³ãžã¢ãã³40ïœã80âã§ïŒæéå
å¿ããããåå¿æ··åç©ãå·åŽããåŸå®æœäŸïŒã®å
äžåŠçãè¡ãªããããèç¹95â98âãåå å 床枬
å®ã«ããæ§é ãåå®ããããšãã§ããã å çŽ åæ C19H32N5SO3 ååé 410.57     èšç®å€(%) 55.58 7.86 17.06 7.81 å®æž¬å€(%) 55.6 7.85 17.1 7.82 å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ïŒâïŒïŒâããããã·ãšãã«ïŒâïŒâããã©ãžã
ãšãã³ïŒAUïŒ004ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâãïŒâïŒïŒâããããã·ãšã
ã«ïŒããã©ãžããïŒâããããšãã³43ïœã80âã§
ïŒæéåå¿ããããåå¿æ··åç©ãå·åŽåŸãå®æœäŸ
ïŒãšåäžåŠçãè¡ãªããããèç¹95â101âãå
å å 床枬å®ã«ããæ§é ãåºå®ããããšãã§ããã å çŽ åæ C18H31N5SO4 ååé 413.55     èšç®å€(%) 52.28 7.56 16.92 7.75 å®æž¬å€(%) 52.3 7.6 17 7.8 å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ïŒïŒâãã³ãžã«ãããªãžãïŒâïŒâããããšãã³
ïŒAUïŒ005ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâïŒïŒâãã³ãžã«ãããªãžãïŒ
âïŒâããããã³52ã°ã©ã ã80âã§ïŒæéåå¿ã
ãããåå¿æ··åç©ãå·åŽåŸå®æœäŸïŒãšåäžåŠçã
è¡ãªããããèç¹102â106âãåå å 床枬å®ã«ã
ãæ§é ãåå®ããããšãã§ããã å çŽ åæ C24H34N4O3SO3 ååé 458.64     èšç®å€(%) 62.85 7.47 12.22 6.99 å®æž¬å€(%) 63 7.5 12.3 7 å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ïŒïŒâãã³ãžã«ããã©ãžãïŒâïŒâããããšãã³
ïŒAUïŒ006ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâïŒïŒâãã³ãžã«âïŒâãã
ã©ãžãïŒâïŒâããããšãã³53ã°ã©ã ã80âã§ïŒ
æéåå¿ããããåå¿æ··åç©ãå·åŽåŸå®æœäŸïŒãš
åäžåŠçãè¡ãªããããèç¹104â108âãåå å
床枬å®ã«ããæ§é ãåå®ããããšãã§ããã å çŽ åæ C23H33N5SO3 ååé 459.61     èšç®å€(%) 60.11 7.24 15.24 6.98 å®æž¬å€(%) 60 7.2 13.3 7 å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ãšãã¬ã³ã€ããâïŒâããããšãã³ïŒAUïŒ
007ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâãšãã¬ã³ã€ããâïŒâãã
ããšãã³26ã°ã©ã ã80âã§ïŒæéåå¿ããããå
å¿æ··åç©ãå·åŽåŸå®æœäŸïŒãšåäžåŠçãè¡ãªãã
ããèç¹107â110âãåå å 床枬å®ã«ããæ§é ã
åå®ããããšãã§ããã å çŽ åæ C14H22N4SO3 ååé 326.46     èšç®å€(%) 51.51 6.79 7.16 9.82 å®æž¬å€(%) 51.6 6.8 17.2 9.8 å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ã·ã¯ããããã¬ã³ã€ããâïŒâããããšãã³
ïŒAUïŒ008ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâã·ã¯ããããã¬ã³ã€ããâ
ïŒâããããšãã³31ã°ã©ã ã80âã§ïŒæéåå¿ã
ãããåå¿æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠç
ãè¡ãªããããèç¹106â109âãåå å 床枬å®ã«
ããæ§é ãåå®ããããšãã§ããã å çŽ åæ C15H24N4SO3 ååé 340.46     èšç®å€(%) 52.33 7.11 16.46 9.42 å®æž¬å€(%) 52.3 7.2 16.5 9.45 å®æœäŸ ïŒ ïŒ®âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒã·ã¯ãã
ãã·ã«ïŒâïŒâãããâïŒïŒïŒâãšãã³ãžã¢ã
ã³ïŒAUïŒ009ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââã·ã¯ãããã·ã«âïŒïŒïŒâ
ãšãã³ãžã¢ãã³37ïœã80âã§ïŒæéåå¿ãããã
åå¿æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãª
ããããèç¹97â99âãåå å 床枬å®ã«ããæ§é
ãåå®ããããšãã§ããã å çŽ åæ C18H30N4SO3 ååé 382.53     èšç®å€(%) 56.52 7.91 14.65 8.38 å®æž¬å€(%) 56.6 8 14.7 8.4 å®æœäŸ 10 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒïŒïŒïŒâ
ã·ã¯ããããµãžãšãã«ïŒâïŒâãããâïŒïŒïŒ
âãšãã³ãžã¢ãã³ïŒAUïŒ010ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââïŒïŒïŒïŒâã·ã¯ããããµãž
ãšãã«âïŒïŒïŒâãšãã³ãžã¢ãã³36ïœã80âã§ïŒ
æéåå¿ããããåå¿æ··åç©ãå·åŽåŸå®æœäŸïŒãš
åäžåŠçãè¡ãªããããèç¹103â107âãåå å
床枬å®ã«ããæ§é ãåå®ããããšãã§ããã å çŽ åæ C18H28N4SO4 ååé 380.53     èšç®å€(%) 56.82 7.42 14.72 8.42 å®æž¬å€(%) 57 7.45 14.5 8.4 å®æœäŸ 11 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒïŒïŒïŒâ
ã·ã¯ããããµãžãšãã«âïŒâã¡ãã«ïŒâïŒâã
ããâïŒïŒïŒâãšãã³ãžã¢ãã³ïŒAUïŒ011ïŒ
ã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããâNâ²âïŒïŒïŒïŒâã·ã¯ããããµãž
ãšãã«âïŒâã¡ãã«ïŒâïŒïŒïŒâãšãã³ãžã¢ãã³
40ïœã80âã§ïŒæéåå¿ããããåå¿æ··åç©ãå·
åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãªããããèç¹99
â103âãåå å 床枬å®ã«ããæ§é ãåå®ããã
ãšãã§ããã å çŽ åæ C19H28N4SO4 ååé 386.52     èšç®å€(%) 59.04 5.75 14.50 8.29 å®æž¬å€(%) 60 5.8 14.4 8.3 å®æœäŸ 12 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒïŒïŒïŒâ
ã·ã¯ããããµãžãšãã«âïŒâãšãã«ïŒâïŒâã
ããâïŒïŒïŒâãšãã³ãžã¢ãã³ïŒAUïŒ012ïŒ
ã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããâNâ²âïŒïŒïŒïŒâã·ã¯ããããµãž
ãšãã«âïŒâãšãã«ïŒâïŒïŒïŒâãšãã³ãžã¢ãã³
41ïœã80âã§ïŒæéåå¿ããããåå¿æ··åç©ãå·
åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãªããããåå å
床枬å®ã«ããæ§é ãåå®ããããããšãã§ããã å çŽ åæ C20H30N4SO3 ååé 406.55     èšç®å€(%) 59.087.4413.78
7.89 å®æž¬å€(%) 60 7.5 13.7
7.9 å®æœäŸ 13 ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ãããµã¡ãã¬ã³ã€ããâïŒâããããšãã³
ïŒAUïŒ013ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâïŒãããµã¡ãã¬ã³ã€ããïŒ
ãšãã³37ã°ã©ã ã80âã§ïŒæéåå¿ããããåå¿
æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãªãã
ããåå å 床枬å®ã«ããæ§é ãåå®ããããšãã§
ããã å çŽ åæ C18H30N4SO3 ååé 382.56     èšç®å€(%) 56.51 7.90 14.65 8.38 å®æž¬å€(%) 56.8 8 14.6 8.4 å®æœäŸ 14 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒãããµã¡
ãã¬ã³ã€ããïŒâïŒâãããâïŒïŒïŒâãšãã³
ãžã¢ãã³ïŒAUïŒ014ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââãããµã¡ãã¬ã³ã€ããâ
ïŒïŒïŒâãšãã³ãžã¢ãã³40ïœã80âã§ïŒæéåå¿
ããããåå¿æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠ
çãè¡ãªããããåå å 床枬å®ã«ããæ§é ãåå®
ããããšãã§ããã å çŽ åæ C18H31N5SO3 ååé 397.57     èšç®å€(%) 54.38 7.86 17.62 8.06 å®æž¬å€(%) 55 7.9 17.7 8 å®æœäŸ 15 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âã·ã¯ããã
ãã«âïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³
ïŒAUïŒ015ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââã·ã¯ããããã«âïŒïŒïŒâ
ãšãã³ãžã¢ãã³40ïœã80âã§ïŒæéåå¿ãããã
åå¿æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãª
ããããèç¹91â94âãåå å 床枬å®ã«ããæ§é
ãåå®ããããšãã§ããã å çŽ åæ C19H33N4SO3 ååé 397.56     èšç®å€(%) 57.40 8.37 14.09 8.06 å®æž¬å€(%) 57.5 8.4 14.1 8.1 å®æœäŸ 16 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âã·ã¯ããã
ãã«âïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³
ïŒAUïŒ016ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââã·ã¯ããããã«âïŒïŒïŒâ
ãšãã³ãžã¢ãã³ã80âã§ïŒæéåå¿ããããåå¿
æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãªãã
ããèç¹97â103âãåå å 床枬å®ã«ããæ§é ã
åå®ããããšãã§ããã å çŽ åæ C17H28N4SO3 ååé 369.46     èšç®å€(%) 55.27 7.64 15.17 8.68 å®æž¬å€(%) 55.3 7.6 15.2 8.7 å®æœäŸ 17 ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ãããªãžãâïŒâããããšãã³ïŒAUïŒ017ïŒ
ã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâãããªãžãâïŒâããããš
ãã³33ã°ã©ã ã80âã§ïŒæéåå¿ããããåå¿æ··
åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãæœãããè
ç¹95â100âãåå å 床枬å®ã«ããæ§é ãåå®ã
ãããšãã§ããã å çŽ åæ C16H26N4SO4 ååé 354.48     èšç®å€(%) 54.2 7.39 15.81 9.04 å®æž¬å€(%) 54.1 7.4 15.8 9.1 å®æœäŸ 18 ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ã¢ã«ããªãâïŒâããããšãã³ïŒAUïŒ018ïŒ
ã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâã¢ã«ããªãâïŒâããããš
ãã³35ã°ã©ã ã80âã§ïŒæéåå¿ããããåå¿æ··
åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãæœãããè
ç¹98â103âãåå å 床枬å®ã«ããæ§é ãåå®ã
ãããšãã§ããã å çŽ åæ C16H26N4SO4 ååé 370.45     èšç®å€(%) 51.88 7.08 15.12 8.65 å®æž¬å€(%) 52 7.1 15.2 8.6 å®æœäŸ 19 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒãšã³ãâ
ïŒâãã«ãã«ãã«ïŒâïŒâãããâïŒïŒïŒâãš
ãã³ãžã¢ãã³ïŒAUïŒ019ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããâNâ²âïŒãšã³ãâïŒâãã«ãã«ã
ã«ïŒâïŒïŒïŒâãšãã³ãžã¢ãã³40ã°ã©ã ã80âã§
ïŒæéåå¿ããããåå¿æ··åç©ãå·åŽåŸãå®æœäŸ
ïŒãšåäžåŠçãæœãããåå å 床枬å®ã«ããæ§é
ãåå®ããããšãã§ãããèç¹95â100â å çŽ åæ C19H30N4SO3 ååé 394.54     èšç®å€(%) 57.84 7.66 14.28 8.13 å®æž¬å€(%) 57.9 7.65 14.3 8.1 å®æœäŸ 20 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒãã«ãã«
ãã³âïŒâã€ã«ïŒâïŒâãããâïŒïŒïŒâãšã
ã³ãžã¢ãã³ïŒAUïŒ020ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââïŒãã«ãã«ãã³âïŒâã€ã«ïŒ
âïŒïŒïŒâãšãã³ãžã¢ãã³40ã°ã©ã ã80âã§ïŒæ
éåå¿ããããåå¿æ··åç©ãå·åŽåŸãå®æœäŸïŒãš
åäžåŠçãè¡ãªããåå å 床枬å®ã«ããæ§é ãå
å®ããããšãã§ãããèç¹96â101â å çŽ åæ C19H28N4SO3 ååé 392.53     èšç®å€(%) 58.14 7.18 14.28 8.17 å®æž¬å€(%) 58.2 7.2 14.3 8.12 å®æœäŸ 21 ïŒâã¢ããâïŒâãããªãžãâïŒâããããšã
ã³ã®åæ ïŒïŒïŒâãã¹âïŒã¡ãã«ããªïŒâïŒâããããšã
ã³16.5ã°ã©ã ãæž©ç±äžã§ããã©ã¯ãããšã¿ã³100
mlã«æº¶è§£ãããããªãžã³8.5ã°ã©ã ãå ããïŒæ
éå ç±éæµãè¡ãªããå·åŽåŸãã¬ã¹ç¶ç¡æ°Žã¢ã³ã¢
ãã¢ã飜åãããŸã§å ããã åå¿æ··åç©ãïŒæéæ¹æããã溶åªãç空äžã§
èžçºããçæç©ãã·ãªã«ã²ã«ã¯ãããã°ã©ãã«ã©
ã ã§ç²Ÿè£œãããç³æ²¹ãšãŒãã«ã次ãã§ãžã¯ãããš
ã¿ã³ã§æŽæµãããçæç©ãåé¢ãããžãšãã«ãšãŒ
ãã«ã§åçµæ¶ããããèç¹121â123âã å®æœäŸ 22 ïŒâã¢ããâïŒâïŒïŒâã¡ãã«ãããªãžãïŒâïŒ
âããããšãã³ã®åæã ãããªãžã³ã®ä»£ãã«ïŒâã¡ãã«ãããªãžã³9.9
ã°ã©ã ãçšãã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³ã§åæ
ãè¡ãªããèç¹125â128âã å®æœäŸ 23 âïŒïŒââãããªãžãã«ïŒâïŒâããããšã
ã³ãžã¢ãã³ã®åæã ãããªãžã³ã®ä»£ãã«ïŒâã¢ããâãšãã«ãããª
ãžã³16.6ã°ã©ã ãçšãã以å€ã¯å®æœäŸ21ãšåäžæ¹
æ³ã§åæãè¡ãªããèç¹118â120âã å®æœäŸ 24 ïŒâã¢ããâïŒâãïŒâïŒïŒâããããã·ãšã
ã«ïŒããã©ãžããâïŒâããããšãã³ã®åæã ïŒïŒïŒâãã¹âïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒâïŒïŒâããããã·ãšãã«ïŒâïŒâããã©ãž
ã³ã®åã¢ã«éãçšãã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³
ã§åæãè¡ãªããèç¹125â128âã å®æœäŸ 25 ïŒâã¢ããâïŒâïŒïŒâãã³ãžã«ãããªãžãïŒâ
ïŒâããããšãã³ã®åæã ïŒïŒïŒâãã¹âïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒâãã³ãžã«ããã©ãžã³ã®åã¢ã«éãçšãã
次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯ãå®æœäŸ21
ãšåäžæ¹æ³ã§åæãè¡ãªããèç¹125â128âã å®æœäŸ 26 ïŒâã¢ããâïŒâïŒïŒâãã³ãžã«âïŒâããã©
ãžãïŒâïŒâããããšãã³ã®åæã ïŒïŒïŒâãã¹âïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒâãã³ãžã«âããã©ãžã³ã®åã¢ã«éãçš
ãã次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœäŸ
21ãšåäžæ¹åã§åæãè¡ãªããèç¹118â121âã å®æœäŸ 27 ïŒâã¢ããâïŒâãšãã¬ã³ã€ããâïŒâããã
ãšãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšãšãã¬ã³ã€ãã³ã®åã¢ã«éãçšãã次ãã§ã¢
ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³
ã§åæãè¡ãªããèç¹98â100âã å®æœäŸ 28 ïŒâã¢ããâïŒâã·ã¯ããããã¬ã³ã€ããâïŒ
âããããšãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšã·ã¯ããããã¬ã³ã€ãã³ã®åã¢ã«éãçšãã
ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœäŸ21ãšåäžæ¹
æ³ã§åæãè¡ãªããèç¹111â115âã å®æœäŸ 29 âã·ã¯ãããã·ã«âïŒâãããâïŒïŒïŒâãš
ãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšã·ã¯ãããã·ã«ã¢ãã³ã®åã¢ã«éãçšãã次
ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœäŸ21ãšå
äžæ¹æ³ã§åæãè¡ãªããèç¹115â118âã å®æœäŸ 30 âïŒïŒïŒïŒâãããµãžãšãã«ïŒâïŒâãããâ
ïŒïŒïŒâãšãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒïŒïŒâãããµãžãšãã«ã¢ãã³ã®åã¢ã«éã
çšãã次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœ
äŸ21ãšåäžæ¹æ³ã§åæãè¡ãªããèç¹120â125
âã å®æœäŸ 31 âïŒïŒïŒïŒâã·ã¯ããããµãžãšãã«âïŒâã¡
ãã«ïŒâïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³
ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒïŒïŒâã·ã¯ããããµãžãšãã«âïŒâãšãã«
ã¢ãã³ã®åã¢ã«éãçšãã次ãã§ã¢ã³ã¢ãã¢ã飜
åããã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³ã§åæãè¡ãª
ããèç¹125â128â å®æœäŸ 32 âïŒïŒïŒïŒâã·ã¯ããããµãžãšãã«âïŒâã¡
ãã«ïŒâïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³ã®
åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒïŒïŒâã·ã¯ããããµãžãšãã«âïŒâã¡ãã«
ã¢ãã³ã®åã¢ã«éãçšãã次ãã§ã¢ã³ã¢ãã¢ã飜
åããã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³ã§åæãè¡ãª
ããèç¹120â125â å®æœäŸ 33 ïŒâã¢ããâïŒâãããµã¡ãã¬ã³ã€ããâïŒâ
ããããšãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšãããµã¡ãã¬ã³ã®åã¢ã«éãçšãã次ãã§é£œ
åããã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³ã§åæãè¡ãª
ããèç¹128â132âã å®æœäŸ 34 âã·ã¯ããããã«âïŒâãããâïŒïŒïŒâãš
ãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹âïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšã·ã¯ããããã«ã¢ãã³ã®åã¢ã«éãçšãã次
ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœäŸ21ãšå
äžæ¹æ³ã«ããåæãè¡ãªããèç¹118â125âã å®æœäŸ 35 âã·ã¯ããã³ãã«âïŒâãããâïŒïŒïŒâãš
ãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšã·ã¯ããã³ãã«ã¢ãã³ã®åã¢ã«éãçšãã次
ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯ãå®æœäŸ21ãš
åäžæ¹æ³ã§åæãè¡ãªããèç¹117â124âã å®æœäŸ 36 ïŒâã¢ãã³âïŒâãããªãžãâïŒâããããšã
ã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšãããªãžã³ã®åã¢ã«éãçšãã次ãã§ã¢ã³ã¢
ãã¢ã飜åããã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³ã§å
æãè¡ãªããèç¹120â125âã å®æœäŸ 37 ïŒâã¢ããâïŒâã¢ã«ããªãâïŒâããããšã
ã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšã¢ã«ããªã³ã®åã¢ã«éãçšãã次ãã§ã¢ã³ã¢
ãã¢ã飜åããã以å€ã¯ãå®æœäŸ21ãšåäžæ¹æ³ã§
åæãè¡ãªããèç¹120â125âã å®æœäŸ 38 âïŒãšã³ãâïŒâãã«ãã«ãã«ïŒâïŒâããã
âïŒïŒïŒâãšãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšãšã³ãâïŒâãã«ããã«ã¢ãã³ã®åã¢ã«éã
çšãã次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœ
äŸ21ãšåäžæ¹æ³ã«ããåæãè¡ãªããèç¹130â
131âã å®æœäŸ 39 âïŒãã«ãã«ãã³âïŒâã€ã«ïŒâïŒâãããâ
ïŒïŒïŒâãšãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšãã«ãã«ãã³âïŒâã€ã«ã¢ãã³ã®åã¢ã«éã
çšãã次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœ
äŸ21ãšåäžæ¹æ³ã§åæãè¡ãªããããèç¹128â
132âã å®æœäŸ 40 âãããµã¡ãã¬ã³ã€ããâïŒâãããâïŒïŒ
ïŒâãšãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒ®âã¢ããâãããµã¡ãã¬ã³ã€ãã³ã®åã¢ã«
éãçšãã次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯
å®æœäŸ21ãšåäžæ¹æ³ã§åæãè¡ãªããããèç¹
127â131âã æ¬çºæã«é¢ããŠç¹å®ã®å ·äœçå®æœæ æ§ãåç §ã
ãªãã詳ãã説æããããããæ¬çºæç¯å²å ã§åœ
æ¥è ãçš®ã ã®å€åœ¢å®æœåã³ä¿®æ£ãè©Šã¿ãããšã¯å®¹
æã«ãããããšãæçœã§ããã
ãŠã¯è¡æ¶²åŠçãè¡æ¶²ååŠçãå°¿çŽ åã³ãã¯ããªã
ããã¯ãã¹ã³ãŒããã¯ãªäž»åšå®ã®æ æ§ã«äœãã®å€
åããããããªãã€ããäœéãã¿ãŒã³åã³æ»äº¡ç
ã«ã€ããŠå€åã¯çŸãããŠããªããæäžéã¯ãå®
éãäºå®ã®äººäœæ²»ççšéãããå€ããã®ã§ãã€
ãã èå æ¯æ§è©Šéšã¯ãã¹ãã©ã°ã»ããŒãªãŒçœåã©ã
ã100äœãé40äœãé60äœãå¹³åäœé125ã°ã©ã ã«
ã€ããŠè¡ãªããããåçš®éšååç©0.25ã50ã100
mgïŒKgã®éãé10äœã®åã°ã«ãŒãã«å¯ŸããŠèåå
60æ¥éã«çµå£æäžãããŸãé20äœã®åã°ã«ãŒãã«
察ããŠèåå15æ¥éã«ãããçµå£æäžããã å被éšååç©ã«ã€ããŠãããŠãŒãžãŒã©ã³ãã»ã
ã¯ã€ãæ ªã®ãŠãµã®æäœãå¹³åäœéïŒKgã40äœã«ã€
ããŠãè©Šéšãè¡ãªããããåååç©ã¯ïŒã20ã
40ã60mgïŒKgã®æäžéã§åä»»åŸïŒæ¥ç®ãã18æ¥ç®
ã«ãããŠçµå£æäžãããã èå æ¯æ§è©Šéšã®çµæã¯ãåŠåš ã®é²è¡åã³åèç©
質ã«å¯Ÿãè² ã®å¹²æžã瀺ããã®ã§ã¯ãªãã€ããæäž
éã¯ãå®éãäºå®ã®äººäœæ²»ççšéãããå€ããã®
ã§ãã€ããè¡šïŒã«ç€ºããAUïŒ010ããAUïŒ020
ãŸã§ã®å šãŠã®ååç©ã«ã€ããŠè©Šéšãè¡ãªãããã å¿è埪ç°å¹æã®è©äŸ¡ã¯ãå被éšååç©ã«ã€ã
ãŠãããŠãŒãžãŒã©ã³ãã»ãã¯ã€ãæ ªãå¹³åäœé
2.5Kgã®éãŠãµã®ïŒäœã«ã€ããŠè¡ãªããããæäž
ã«éãåãŠã¶ã®ã«éº»é ãæœããçµå£æäžã®å Žå
ïŒïŒäœïŒã¯100mgïŒKgãéè泚å°ã®å ŽåïŒïŒäœïŒ
ã¯ã20mgïŒKgã®æäžéãšããããã®çµæãåè
å§ãåŒåžæ¯å¹ åã³ã²ã床ãåã³å¿é»å³æ²ç·ã«äœã
ã®å€åããªãã€ããAUïŒ001ããAUïŒ020ãŸã§
ã®å šãŠã®ååç©ã«ã€ããŠè©Šéšãè¡ãªãããã æ¬çºæååç©ã®å¹æã調ã¹ããããã¹ãã©ã°ã»
ããŒãªãŒæ ªãå¹³åäœé200ã°ã©ã ã®éåã³éã©ã
ã50äœãäŸè©Šãããã é£é€äžã®ãããæ€äœã¯å¹œéçµçŽ®ã«äŸããããã
è¡åŸïŒæéããŠè¢«æ€ååç©ïŒã310ã30mgïŒKgã®
éãåã¯ã·ã¡ããžã³ïŒã10ã30ã100mgïŒKgãªã
ãã©ãããžã³ïŒãïŒã10ã30mgïŒKgã®éã§æäžã
è¡ãªãããã æ¬çºæååç©ãã·ã¡ããžã³åã³ã©ãããžã³ã®å š
ãŠã®æäžã«ã€ããŠå¹œéçµçŽ®ã«ããããããããè
朰çé»æ¢ã«ã€ããŠææã®çµæãäžããã æ¬çºæã«é¢ãã被æ€ååç©ã®æŽ»æ§ã¯ã·ã¡ããžã³
ã®çŽïŒåãã©ãããžã³ã®1.2ã1.3åã§ãã€ãã
AUïŒ001ããAUïŒ020ãŸã§å šãŠã®ååç©ã«ã€ã
ãŠèª¿ã¹ãããã 貯çã«åºã朰çã«å¯Ÿããæ¬çºæååç©ã®å¹æã
調ã¹ãããã«ã¹ãã©ã°ã»ããŒãªãŒæ ªãå¹³åäœéçŽ
200ã°ã©ã ã®çœåã©ããé60äœãäŸããããæ€äœ
ã®ïŒã€ã®ã°ã«ãŒãã¯è³Šåœ¢å€ã®ã¿ãäžãããã³ã³ã
ããŒã«æ€äœãšããŠæ±ããããïŒã€ã®æ€äœã°ã«ãŒã
ã¯ïŒåã³10mgïŒKgã®æäžéã§è¢«æ€ååç©ãçµå£æ
äžããŠååŠçãæœãããã貯ççšã±ãŒãžã«çœ®ãã
ãåã«ã·ã¡ããžã³10åã³20mgïŒKgã®çµå£æäžãå
ããïŒã€ã®æ€äœã°ã«ãŒããå ãããããæçµç
ã«ã貯ççšã±ãŒãžã«çœ®ãããåã«ã©ãããžã³ïŒå
ã³10mgïŒKgã®çµå£æäžãåããïŒã€ã®æ€äœã°ã«ãŒ
ããå ããããã å·é貯çã«ãã€ãŠå®éšçã«é»æ¢ãããè朰çé »
床ã¯ã3.3åéã®ã·ã¡ããžã³åã³1.1ã1.2åã®ã©ã
ããžã³æäžã«ãããŠèŠ³å¯ããããããé¡èãªçšåºŠ
ã«ãæ¬çºæååç©æäžã«ãããŠæžããããã
AUïŒ001ããAUïŒ020ãŸã§ã®å šãŠã®ååç©ã«ã€
ããŠè©Šéšãè¡ãªãããã æ¬çºæååç©ã®è²¯çã«åºã朰çã«å¯Ÿããæ²»çç
å¹æã調ã¹ããããã¹ãã©ã°ã»ããŒãªãŒæ ªãå¹³å
äœé200ã°ã©ã ã®éçœåã©ãã30äœãçšããããã
æ€äœã¯16æé絶é£ããã枩床21âã§24æéã«ãã
ã貯çã±ãŒãžã«å容ãããããããåŸã«éæŸã
ããæé·15æ¥éã«ããã€ãŠäžèšèŠé ã§ååç©ãæ
äžãããã 第ïŒã°ã«ãŒãïŒïŒæ¥åŸïŒïŒæ€äœïŒåã³15æ¥åŸïŒïŒ
æ€äœïŒã«äŸãããã³ã³ãããŒã«æ€äœ 第ïŒã°ã«ãŒãïŒïŒæ¥åŸïŒïŒæ€äœïŒåã³15æ¥åŸïŒïŒ
æ€äœïŒã«è¢«æ€ååç©2.5mgïŒKgãçµå£æäžãã
ãæ€äœ 第ïŒã°ã«ãŒãïŒïŒæ¥åŸïŒïŒæ€äœïŒåã³15æ¥åŸïŒïŒ
æ€äœïŒã«è¢«æ€ååç©ïŒmgïŒKgãçµå£æäžããã
æ€äœ 被æ€ååç©ã®ç¹°è¿ãæäžã¯è²¯çã«åºã朰çã®ç¢
çåãå©ãããAUïŒ001ããAUïŒ020ãŸã§ã®å š
ãŠã®ååç©ã«ã€ããŠè©Šéšãè¡ãªãããã ã¹ãã©ã°ã»ããŒãªãŒæ ªã®éçœåã©ããã«å¯Ÿã
0.25åã³0.50mgïŒKgã®çµå£æäžãåã³0.10åã³
0.20mgïŒKgã®éèå æäžãæœãããAUïŒ001ãã
AUïŒ020ãŸã§ã®æ¬çºæååç©ã¯ãèå åæ³ç©å
ã³èå é žåºŠãããªãã®éã§æå¶ããè液ã®PHãå€
åãããåå ãšããªããªãã€ãã ããã©ã¬ã¹ããªã³ã«åºãèé žéå€ã«å¯Ÿããæ¬çº
æååç©ã®å¹æã調ã¹ããããã¹ãã©ã°ã»ããŒãª
ãŒæ ªãå¹³åäœé180ã°ã©ã ã®éçœåã©ãã30äœã
äŸãããã 16æé絶é£ãããæ€äœã¯ãšãã«ãŠã¬ã¿ã³ãçšã
ãŠéº»é äžã«ããããã幜éåã³é£éé éšçµçŽ®ã®
åŸãæ€äœã®èäžã«ã«ããŠãŒã¬ãæ¿å ¥ããã€ã·ã€ã
ã·ãã©ãããžã€ããïŒãžãšãŒïŒãã¢ãŒãã³ã«ïŒ
18ã93â1968ïŒIshil and ShinorakiãJap.J.
Pharmacol.18ã93â1968ïŒã®æ¹æ³ã«åŸã€ãŠèå
åæ³ç©ãéããããããã®æ§ã«åŠçœ®ãããæ€äœã«
ç®äžæ³šå°ã«ãã0.5mgïŒKgã®ããã©ã¬ã¹ããªã³ã
æäžãããããã®æäžãšåæã«ãæ€äœã¯çç溶液
ïŒã³ã³ãããŒã«ïŒåã¯éè泚å°ã«ãã被æ€ååç©
0.25åã³0.5mgïŒKgã®æäžãæœãããã ããã©ã¬ã¹ããªã³æäžã«ããéé žåºŠã¯è¢«æ€åå
ç©ã®éèæäžã«ããããªãã®çšåºŠæå¶ãããã
AUïŒ001ããAUïŒ020ãŸã§ã®ååç©ãè©Šéšã«äŸ
ãããã åŒïŒïŒã®ååç©åã³ãããã®è¬ç©çã«èš±å®¹ã
ããå¡©ã¯ãé«æŽ»æ§ãæããå®è³ªçã«å¯äœçšãæã
ãªãããè¬ç©çµæç©ã®åœ¢æã«ãããŠæŽ»æ§èŠçŽ ãšã
ãŠç¹ã«æçšã§ããããããã€ãŠãæ¬çºæã¯ããã
ã®ååç©ã掻æ§èŠçŽ ãšããŠïŒçš®åã¯ïŒçš®ä»¥äžæå¹
éå«æããè¬ç©çµæç©ã«ãé¢ãããã®ã§ãããã
ã®ãŸãŸãããããã¯è¬å¹ãæããå ¬ç¥ååç©ã§ã
ã€ãŠäžèšåŒïŒïŒã®ååç©ãšæ··å䜵çšããŠãé害
ãåŒãèµ·ããååŠå€åãçžäºæ®æäœçšã瀺ãããš
ã®ãªãååç©ãåã³ïŒåã¯è³Šåœ¢å€ãåžéå€ã溶å€
åã³ïŒåã¯è¬ç©çã«èš±å®¹ãããå¢éå€ãšå ±ã«çšã
ãããã 該è¬ç©çµæç©ã¯ãçµå£ãçŽè žã泚å°åã¯å±éšæ
äžçšãšããŠèª¿è£œããããšãã§ãããäŸãã°ãã«ã
ã»ã«ãé å€ãæ¯éâæŸåºåé å€ãïŒåæäžåè¢
è©°ãåè¬ãè»éªšçã®åºåç¶ã溶液ãããã ã液ã
ä¹³å€çã®æ¶²ç¶ãšããããã®æ§ãªåœ¢æ åã¯å³æ調å
çšãšããŠçšãããããåèšè¬ç©çµæç©ã®å šãŠã¯ã
åžéå€ã賊圢å€ã溶å€åã³ïŒåã¯å¢éå€ãšããŠå ¬
ç¥ã®ãã®ãå«ãããã«èª¿è£œããããšãã§ããããŸ
ã調補æ¹æ³ãšããŠå ¬ç¥ã®æ¹æ³ãçšããããšãã§
ããäŸãã°ããã¯ãããžã¢ ãã¢ãŒãã·ãŠãŒãã€
ã«ãã·ã«ããã»ã«ãµãã€ãªâããã«ã»ããµã«ãã
ãŽãªã¢ã«ãã€ã«âãã©ã1972ïŒâTecnologia
FarmaceuticaâãSilvano CasadioâPubl.
Cisalpino ColiardicaâMilano1972ïŒã«ååã«èš
èŒãããŠããã æ¬çºæååç©ã¯ãã®ãŸãŸåã¯å¡©ã®åœ¢ã§ãïŒæ¥ã
ãã0.2ã50mgïŒKgã奜ãŸããã¯0.5ã2.0mgïŒKgã®
éã§æäžããããšãã§ããè¬éåŠçã«ãäŸãã°
10ã20ã30ã50ã100ã200ã250åã¯500mgã®éã§
ïŒæ¥ãããïŒãïŒåã«ãããŠæç¶çã«æäžããã®
ãæå©ã§ããã æ¬çºæã¯ããŸããåŒïŒïŒã®ååç©åã³ãã®è¬
ç©çã«èš±å®¹ãããå¡©ã®è£œé æ¹æ³ã«ãé¢ããŠããã
ãã®æ¹æ³ã¯åŒïŒïŒïŒ ã®ïŒâãããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ãâïŒâ
ãã©ãã«ãã¡ãã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€
ããåŒïŒïŒïŒ ïŒåŒäžãã¯åè¿°ã®æå³ãæãããïŒ ã®ååç©ãã枩床80âã§åå¿ããããããåŸãåŸ
ãããåŒïŒïŒã®ååç©ãåé¢ããå¿ èŠã«å¿ããŠ
å¡©åããããšã«ããå®æœãããã奜ãŸããã¯ãåŒ
ïŒïŒã®ååç©ãéå°é䜿çšãããåå¿ã¯ïŒæé
ç¶è¡ãããã åŒïŒïŒã®ååç©ã¯ãæ¬çºæã®ä»ã®äž»é¡ãæ§æ
ãã補é æ¹æ³ãå³ã¡ãåŒïŒïŒïŒ ã®ïŒïŒïŒãã¹ïŒã¡ãã«ããªïŒâïŒâããããšãã¬
ã³ãåŒïŒïŒïŒRHïŒïŒ²ã¯åè¿°ã®æå³ãæããïŒãš
åå¿ããã次ãã§ã¢ã³ã¢ãã¢ãšåå¿ãããæ¹æ³ã«
ãã€ãŠè£œé ããããšãã§ããããã®åå¿ã¯å®çšç
ã«ã¯ææ©æº¶åªäžã奜ãŸããã¯ããã©ã¯ãããšã¿ã³
äžã§è¡ãªããããåŸãããååç©ã®ç²Ÿè£œã¯ã·ãªã«
ã²ã«ã«ã©ã ééåã³åçµæ¶ã«ããè¡ãªãããã åŒïŒïŒã®ååç©ã¯ã€ã¿ãªã¢åœç¹èš±åºé¡
19473AïŒ82ïŒæ¬é¡ãšåäžåºé¡äººïŒã«èšèŒã®æ¹æ³ã«
ãã€ãŠèª¿è£œããããšãã§ããã åŸãããåŒïŒïŒã®ååç©ã¯åœæ¥è ã«å ¬ç¥ã®æ¹
æ³ã«ãã€ãŠå®¹æã«åé¢ããããšãã§ãããäŸãã°
溶åªããã®åçµæ¶ãªã©ãçšããããšãã§ããã奜
ãŸããã¯ãçšãã溶åªãšããŠæ°Žâãšãã«ã¢ã«ã³ãŒ
ã«æ··æ¶²ãæããããšãã§ããã å¿ èŠã«ããè¡ãªãããå¡©åã¯åœæ¥è ã«å ¬ç¥ã®æ¹
æ³ãäŸãã°é©å®ã®é žãå ããããšã«ãã€ãŠè¡ãªã
ããšãã§ããã 次ã«å®æœäŸã瀺ããŠæ¬çºæãæŽã«è©³ãã説æã
ãããæ¬çºæã®å®æœã®æ æ§ã¯ãããã«éå®ãããª
ãã å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒâ
ãããªãžãâïŒâããããšãã³ïŒAUïŒ001ïŒ
ã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ïŒããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ã®ïŒâã¢ããâïŒâãããªãžãâïŒâããããš
ãã³35ã°ã©ã ã80âã§ïŒæéåå¿ããããåå¿æ··
åç©ãå·åŽããšãã«ãšãŒãã«äžã«ãšãã次ãã§
éããæ²æŸ±ããšãã«ã¢ã«ã³ãŒã«ã«æº¶è§£ãå床氎äž
ã§æ²æŸ±ããããåŸãããæ²æŸ±ãæ°Žã»ãšãã«ã¢ã«ã³
ãŒã«æ··æ¶²ã§åçµæ¶ããããèç¹101â105âãåå
å 床枬å®ã«ããæ§é ãåå®ããããšãã§ããã å çŽ åæ C17H28N4O3S ååé 368.481     èšç®å€(%) 55.51 7.66 15.21 8.70 å®æž¬å€(%) 55.8 7.5 15.2 8.60 å®æœäŸ ïŒ ïŒâãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãã¢ããâïŒâïŒïŒ
âã¡ãã«ãããªãžãïŒâïŒâããããšãã³
ïŒAUïŒ002ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâïŒïŒâã¡ãã«ãããªãžãïŒâ
ïŒâããããšãã³37ã°ã©ã ã80âã§ïŒæéåå¿ã
ãããå·åŽåŸå®æœäŸïŒãšåäžåŠçãè¡ãªãããã
èç¹105â110âãåå å 床枬å®ã«ããæ§é ãåå®
ããããšãã§ããã å çŽ åæ C18H30N4O3S ååé 382.508     èšç®å€(%) 56.52 7.91 14.658.38 å®æž¬å€(%) 57 7.90 15 8.35 å®æœäŸ ïŒ ïŒ®âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒïŒ®âãšã
ã«ãããªãžãã«ïŒâïŒâãããâïŒïŒïŒâãšã
ã³ãžã¢ãã³ïŒAUïŒ003ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââïŒïŒ®âãšãã«ãããªãžãã«ïŒ
âïŒïŒïŒâãšãã³ãžã¢ãã³40ïœã80âã§ïŒæéå
å¿ããããåå¿æ··åç©ãå·åŽããåŸå®æœäŸïŒã®å
äžåŠçãè¡ãªããããèç¹95â98âãåå å 床枬
å®ã«ããæ§é ãåå®ããããšãã§ããã å çŽ åæ C19H32N5SO3 ååé 410.57     èšç®å€(%) 55.58 7.86 17.06 7.81 å®æž¬å€(%) 55.6 7.85 17.1 7.82 å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ïŒâïŒïŒâããããã·ãšãã«ïŒâïŒâããã©ãžã
ãšãã³ïŒAUïŒ004ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâãïŒâïŒïŒâããããã·ãšã
ã«ïŒããã©ãžããïŒâããããšãã³43ïœã80âã§
ïŒæéåå¿ããããåå¿æ··åç©ãå·åŽåŸãå®æœäŸ
ïŒãšåäžåŠçãè¡ãªããããèç¹95â101âãå
å å 床枬å®ã«ããæ§é ãåºå®ããããšãã§ããã å çŽ åæ C18H31N5SO4 ååé 413.55     èšç®å€(%) 52.28 7.56 16.92 7.75 å®æž¬å€(%) 52.3 7.6 17 7.8 å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ïŒïŒâãã³ãžã«ãããªãžãïŒâïŒâããããšãã³
ïŒAUïŒ005ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâïŒïŒâãã³ãžã«ãããªãžãïŒ
âïŒâããããã³52ã°ã©ã ã80âã§ïŒæéåå¿ã
ãããåå¿æ··åç©ãå·åŽåŸå®æœäŸïŒãšåäžåŠçã
è¡ãªããããèç¹102â106âãåå å 床枬å®ã«ã
ãæ§é ãåå®ããããšãã§ããã å çŽ åæ C24H34N4O3SO3 ååé 458.64     èšç®å€(%) 62.85 7.47 12.22 6.99 å®æž¬å€(%) 63 7.5 12.3 7 å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ïŒïŒâãã³ãžã«ããã©ãžãïŒâïŒâããããšãã³
ïŒAUïŒ006ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâïŒïŒâãã³ãžã«âïŒâãã
ã©ãžãïŒâïŒâããããšãã³53ã°ã©ã ã80âã§ïŒ
æéåå¿ããããåå¿æ··åç©ãå·åŽåŸå®æœäŸïŒãš
åäžåŠçãè¡ãªããããèç¹104â108âãåå å
床枬å®ã«ããæ§é ãåå®ããããšãã§ããã å çŽ åæ C23H33N5SO3 ååé 459.61     èšç®å€(%) 60.11 7.24 15.24 6.98 å®æž¬å€(%) 60 7.2 13.3 7 å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ãšãã¬ã³ã€ããâïŒâããããšãã³ïŒAUïŒ
007ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâãšãã¬ã³ã€ããâïŒâãã
ããšãã³26ã°ã©ã ã80âã§ïŒæéåå¿ããããå
å¿æ··åç©ãå·åŽåŸå®æœäŸïŒãšåäžåŠçãè¡ãªãã
ããèç¹107â110âãåå å 床枬å®ã«ããæ§é ã
åå®ããããšãã§ããã å çŽ åæ C14H22N4SO3 ååé 326.46     èšç®å€(%) 51.51 6.79 7.16 9.82 å®æž¬å€(%) 51.6 6.8 17.2 9.8 å®æœäŸ ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ã·ã¯ããããã¬ã³ã€ããâïŒâããããšãã³
ïŒAUïŒ008ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâã·ã¯ããããã¬ã³ã€ããâ
ïŒâããããšãã³31ã°ã©ã ã80âã§ïŒæéåå¿ã
ãããåå¿æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠç
ãè¡ãªããããèç¹106â109âãåå å 床枬å®ã«
ããæ§é ãåå®ããããšãã§ããã å çŽ åæ C15H24N4SO3 ååé 340.46     èšç®å€(%) 52.33 7.11 16.46 9.42 å®æž¬å€(%) 52.3 7.2 16.5 9.45 å®æœäŸ ïŒ ïŒ®âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒã·ã¯ãã
ãã·ã«ïŒâïŒâãããâïŒïŒïŒâãšãã³ãžã¢ã
ã³ïŒAUïŒ009ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââã·ã¯ãããã·ã«âïŒïŒïŒâ
ãšãã³ãžã¢ãã³37ïœã80âã§ïŒæéåå¿ãããã
åå¿æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãª
ããããèç¹97â99âãåå å 床枬å®ã«ããæ§é
ãåå®ããããšãã§ããã å çŽ åæ C18H30N4SO3 ååé 382.53     èšç®å€(%) 56.52 7.91 14.65 8.38 å®æž¬å€(%) 56.6 8 14.7 8.4 å®æœäŸ 10 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒïŒïŒïŒâ
ã·ã¯ããããµãžãšãã«ïŒâïŒâãããâïŒïŒïŒ
âãšãã³ãžã¢ãã³ïŒAUïŒ010ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââïŒïŒïŒïŒâã·ã¯ããããµãž
ãšãã«âïŒïŒïŒâãšãã³ãžã¢ãã³36ïœã80âã§ïŒ
æéåå¿ããããåå¿æ··åç©ãå·åŽåŸå®æœäŸïŒãš
åäžåŠçãè¡ãªããããèç¹103â107âãåå å
床枬å®ã«ããæ§é ãåå®ããããšãã§ããã å çŽ åæ C18H28N4SO4 ååé 380.53     èšç®å€(%) 56.82 7.42 14.72 8.42 å®æž¬å€(%) 57 7.45 14.5 8.4 å®æœäŸ 11 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒïŒïŒïŒâ
ã·ã¯ããããµãžãšãã«âïŒâã¡ãã«ïŒâïŒâã
ããâïŒïŒïŒâãšãã³ãžã¢ãã³ïŒAUïŒ011ïŒ
ã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããâNâ²âïŒïŒïŒïŒâã·ã¯ããããµãž
ãšãã«âïŒâã¡ãã«ïŒâïŒïŒïŒâãšãã³ãžã¢ãã³
40ïœã80âã§ïŒæéåå¿ããããåå¿æ··åç©ãå·
åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãªããããèç¹99
â103âãåå å 床枬å®ã«ããæ§é ãåå®ããã
ãšãã§ããã å çŽ åæ C19H28N4SO4 ååé 386.52     èšç®å€(%) 59.04 5.75 14.50 8.29 å®æž¬å€(%) 60 5.8 14.4 8.3 å®æœäŸ 12 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒïŒïŒïŒâ
ã·ã¯ããããµãžãšãã«âïŒâãšãã«ïŒâïŒâã
ããâïŒïŒïŒâãšãã³ãžã¢ãã³ïŒAUïŒ012ïŒ
ã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããâNâ²âïŒïŒïŒïŒâã·ã¯ããããµãž
ãšãã«âïŒâãšãã«ïŒâïŒïŒïŒâãšãã³ãžã¢ãã³
41ïœã80âã§ïŒæéåå¿ããããåå¿æ··åç©ãå·
åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãªããããåå å
床枬å®ã«ããæ§é ãåå®ããããããšãã§ããã å çŽ åæ C20H30N4SO3 ååé 406.55     èšç®å€(%) 59.087.4413.78
7.89 å®æž¬å€(%) 60 7.5 13.7
7.9 å®æœäŸ 13 ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ãããµã¡ãã¬ã³ã€ããâïŒâããããšãã³
ïŒAUïŒ013ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâïŒãããµã¡ãã¬ã³ã€ããïŒ
ãšãã³37ã°ã©ã ã80âã§ïŒæéåå¿ããããåå¿
æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãªãã
ããåå å 床枬å®ã«ããæ§é ãåå®ããããšãã§
ããã å çŽ åæ C18H30N4SO3 ååé 382.56     èšç®å€(%) 56.51 7.90 14.65 8.38 å®æž¬å€(%) 56.8 8 14.6 8.4 å®æœäŸ 14 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒãããµã¡
ãã¬ã³ã€ããïŒâïŒâãããâïŒïŒïŒâãšãã³
ãžã¢ãã³ïŒAUïŒ014ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââãããµã¡ãã¬ã³ã€ããâ
ïŒïŒïŒâãšãã³ãžã¢ãã³40ïœã80âã§ïŒæéåå¿
ããããåå¿æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠ
çãè¡ãªããããåå å 床枬å®ã«ããæ§é ãåå®
ããããšãã§ããã å çŽ åæ C18H31N5SO3 ååé 397.57     èšç®å€(%) 54.38 7.86 17.62 8.06 å®æž¬å€(%) 55 7.9 17.7 8 å®æœäŸ 15 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âã·ã¯ããã
ãã«âïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³
ïŒAUïŒ015ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââã·ã¯ããããã«âïŒïŒïŒâ
ãšãã³ãžã¢ãã³40ïœã80âã§ïŒæéåå¿ãããã
åå¿æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãª
ããããèç¹91â94âãåå å 床枬å®ã«ããæ§é
ãåå®ããããšãã§ããã å çŽ åæ C19H33N4SO3 ååé 397.56     èšç®å€(%) 57.40 8.37 14.09 8.06 å®æž¬å€(%) 57.5 8.4 14.1 8.1 å®æœäŸ 16 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âã·ã¯ããã
ãã«âïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³
ïŒAUïŒ016ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââã·ã¯ããããã«âïŒïŒïŒâ
ãšãã³ãžã¢ãã³ã80âã§ïŒæéåå¿ããããåå¿
æ··åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãè¡ãªãã
ããèç¹97â103âãåå å 床枬å®ã«ããæ§é ã
åå®ããããšãã§ããã å çŽ åæ C17H28N4SO3 ååé 369.46     èšç®å€(%) 55.27 7.64 15.17 8.68 å®æž¬å€(%) 55.3 7.6 15.2 8.7 å®æœäŸ 17 ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ãããªãžãâïŒâããããšãã³ïŒAUïŒ017ïŒ
ã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâãããªãžãâïŒâããããš
ãã³33ã°ã©ã ã80âã§ïŒæéåå¿ããããåå¿æ··
åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãæœãããè
ç¹95â100âãåå å 床枬å®ã«ããæ§é ãåå®ã
ãããšãã§ããã å çŽ åæ C16H26N4SO4 ååé 354.48     èšç®å€(%) 54.2 7.39 15.81 9.04 å®æž¬å€(%) 54.1 7.4 15.8 9.1 å®æœäŸ 18 ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ãã¢ããâïŒâ
ã¢ã«ããªãâïŒâããããšãã³ïŒAUïŒ018ïŒ
ã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâã¢ããâïŒâã¢ã«ããªãâïŒâããããš
ãã³35ã°ã©ã ã80âã§ïŒæéåå¿ããããåå¿æ··
åç©ãå·åŽåŸãå®æœäŸïŒãšåäžåŠçãæœãããè
ç¹98â103âãåå å 床枬å®ã«ããæ§é ãåå®ã
ãããšãã§ããã å çŽ åæ C16H26N4SO4 ååé 370.45     èšç®å€(%) 51.88 7.08 15.12 8.65 å®æž¬å€(%) 52 7.1 15.2 8.6 å®æœäŸ 19 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒãšã³ãâ
ïŒâãã«ãã«ãã«ïŒâïŒâãããâïŒïŒïŒâãš
ãã³ãžã¢ãã³ïŒAUïŒ019ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããâNâ²âïŒãšã³ãâïŒâãã«ãã«ã
ã«ïŒâïŒïŒïŒâãšãã³ãžã¢ãã³40ã°ã©ã ã80âã§
ïŒæéåå¿ããããåå¿æ··åç©ãå·åŽåŸãå®æœäŸ
ïŒãšåäžåŠçãæœãããåå å 床枬å®ã«ããæ§é
ãåå®ããããšãã§ãããèç¹95â100â å çŽ åæ C19H30N4SO3 ååé 394.54     èšç®å€(%) 57.84 7.66 14.28 8.13 å®æž¬å€(%) 57.9 7.65 14.3 8.1 å®æœäŸ 20 âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ãããªããšãã«ãâNâ²âïŒãã«ãã«
ãã³âïŒâã€ã«ïŒâïŒâãããâïŒïŒïŒâãšã
ã³ãžã¢ãã³ïŒAUïŒ020ïŒã®åæ ïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ããã«ã
ãªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã24.54ã°ã©
ã ãšïŒâãããââïŒãã«ãã«ãã³âïŒâã€ã«ïŒ
âïŒïŒïŒâãšãã³ãžã¢ãã³40ã°ã©ã ã80âã§ïŒæ
éåå¿ããããåå¿æ··åç©ãå·åŽåŸãå®æœäŸïŒãš
åäžåŠçãè¡ãªããåå å 床枬å®ã«ããæ§é ãå
å®ããããšãã§ãããèç¹96â101â å çŽ åæ C19H28N4SO3 ååé 392.53     èšç®å€(%) 58.14 7.18 14.28 8.17 å®æž¬å€(%) 58.2 7.2 14.3 8.12 å®æœäŸ 21 ïŒâã¢ããâïŒâãããªãžãâïŒâããããšã
ã³ã®åæ ïŒïŒïŒâãã¹âïŒã¡ãã«ããªïŒâïŒâããããšã
ã³16.5ã°ã©ã ãæž©ç±äžã§ããã©ã¯ãããšã¿ã³100
mlã«æº¶è§£ãããããªãžã³8.5ã°ã©ã ãå ããïŒæ
éå ç±éæµãè¡ãªããå·åŽåŸãã¬ã¹ç¶ç¡æ°Žã¢ã³ã¢
ãã¢ã飜åãããŸã§å ããã åå¿æ··åç©ãïŒæéæ¹æããã溶åªãç空äžã§
èžçºããçæç©ãã·ãªã«ã²ã«ã¯ãããã°ã©ãã«ã©
ã ã§ç²Ÿè£œãããç³æ²¹ãšãŒãã«ã次ãã§ãžã¯ãããš
ã¿ã³ã§æŽæµãããçæç©ãåé¢ãããžãšãã«ãšãŒ
ãã«ã§åçµæ¶ããããèç¹121â123âã å®æœäŸ 22 ïŒâã¢ããâïŒâïŒïŒâã¡ãã«ãããªãžãïŒâïŒ
âããããšãã³ã®åæã ãããªãžã³ã®ä»£ãã«ïŒâã¡ãã«ãããªãžã³9.9
ã°ã©ã ãçšãã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³ã§åæ
ãè¡ãªããèç¹125â128âã å®æœäŸ 23 âïŒïŒââãããªãžãã«ïŒâïŒâããããšã
ã³ãžã¢ãã³ã®åæã ãããªãžã³ã®ä»£ãã«ïŒâã¢ããâãšãã«ãããª
ãžã³16.6ã°ã©ã ãçšãã以å€ã¯å®æœäŸ21ãšåäžæ¹
æ³ã§åæãè¡ãªããèç¹118â120âã å®æœäŸ 24 ïŒâã¢ããâïŒâãïŒâïŒïŒâããããã·ãšã
ã«ïŒããã©ãžããâïŒâããããšãã³ã®åæã ïŒïŒïŒâãã¹âïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒâïŒïŒâããããã·ãšãã«ïŒâïŒâããã©ãž
ã³ã®åã¢ã«éãçšãã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³
ã§åæãè¡ãªããèç¹125â128âã å®æœäŸ 25 ïŒâã¢ããâïŒâïŒïŒâãã³ãžã«ãããªãžãïŒâ
ïŒâããããšãã³ã®åæã ïŒïŒïŒâãã¹âïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒâãã³ãžã«ããã©ãžã³ã®åã¢ã«éãçšãã
次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯ãå®æœäŸ21
ãšåäžæ¹æ³ã§åæãè¡ãªããèç¹125â128âã å®æœäŸ 26 ïŒâã¢ããâïŒâïŒïŒâãã³ãžã«âïŒâããã©
ãžãïŒâïŒâããããšãã³ã®åæã ïŒïŒïŒâãã¹âïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒâãã³ãžã«âããã©ãžã³ã®åã¢ã«éãçš
ãã次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœäŸ
21ãšåäžæ¹åã§åæãè¡ãªããèç¹118â121âã å®æœäŸ 27 ïŒâã¢ããâïŒâãšãã¬ã³ã€ããâïŒâããã
ãšãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšãšãã¬ã³ã€ãã³ã®åã¢ã«éãçšãã次ãã§ã¢
ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³
ã§åæãè¡ãªããèç¹98â100âã å®æœäŸ 28 ïŒâã¢ããâïŒâã·ã¯ããããã¬ã³ã€ããâïŒ
âããããšãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšã·ã¯ããããã¬ã³ã€ãã³ã®åã¢ã«éãçšãã
ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœäŸ21ãšåäžæ¹
æ³ã§åæãè¡ãªããèç¹111â115âã å®æœäŸ 29 âã·ã¯ãããã·ã«âïŒâãããâïŒïŒïŒâãš
ãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšã·ã¯ãããã·ã«ã¢ãã³ã®åã¢ã«éãçšãã次
ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœäŸ21ãšå
äžæ¹æ³ã§åæãè¡ãªããèç¹115â118âã å®æœäŸ 30 âïŒïŒïŒïŒâãããµãžãšãã«ïŒâïŒâãããâ
ïŒïŒïŒâãšãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒïŒïŒâãããµãžãšãã«ã¢ãã³ã®åã¢ã«éã
çšãã次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœ
äŸ21ãšåäžæ¹æ³ã§åæãè¡ãªããèç¹120â125
âã å®æœäŸ 31 âïŒïŒïŒïŒâã·ã¯ããããµãžãšãã«âïŒâã¡
ãã«ïŒâïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³
ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒïŒïŒâã·ã¯ããããµãžãšãã«âïŒâãšãã«
ã¢ãã³ã®åã¢ã«éãçšãã次ãã§ã¢ã³ã¢ãã¢ã飜
åããã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³ã§åæãè¡ãª
ããèç¹125â128â å®æœäŸ 32 âïŒïŒïŒïŒâã·ã¯ããããµãžãšãã«âïŒâã¡
ãã«ïŒâïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³ã®
åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒïŒïŒâã·ã¯ããããµãžãšãã«âïŒâã¡ãã«
ã¢ãã³ã®åã¢ã«éãçšãã次ãã§ã¢ã³ã¢ãã¢ã飜
åããã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³ã§åæãè¡ãª
ããèç¹120â125â å®æœäŸ 33 ïŒâã¢ããâïŒâãããµã¡ãã¬ã³ã€ããâïŒâ
ããããšãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšãããµã¡ãã¬ã³ã®åã¢ã«éãçšãã次ãã§é£œ
åããã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³ã§åæãè¡ãª
ããèç¹128â132âã å®æœäŸ 34 âã·ã¯ããããã«âïŒâãããâïŒïŒïŒâãš
ãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹âïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšã·ã¯ããããã«ã¢ãã³ã®åã¢ã«éãçšãã次
ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœäŸ21ãšå
äžæ¹æ³ã«ããåæãè¡ãªããèç¹118â125âã å®æœäŸ 35 âã·ã¯ããã³ãã«âïŒâãããâïŒïŒïŒâãš
ãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšã·ã¯ããã³ãã«ã¢ãã³ã®åã¢ã«éãçšãã次
ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯ãå®æœäŸ21ãš
åäžæ¹æ³ã§åæãè¡ãªããèç¹117â124âã å®æœäŸ 36 ïŒâã¢ãã³âïŒâãããªãžãâïŒâããããšã
ã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšãããªãžã³ã®åã¢ã«éãçšãã次ãã§ã¢ã³ã¢
ãã¢ã飜åããã以å€ã¯å®æœäŸ21ãšåäžæ¹æ³ã§å
æãè¡ãªããèç¹120â125âã å®æœäŸ 37 ïŒâã¢ããâïŒâã¢ã«ããªãâïŒâããããšã
ã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšã¢ã«ããªã³ã®åã¢ã«éãçšãã次ãã§ã¢ã³ã¢
ãã¢ã飜åããã以å€ã¯ãå®æœäŸ21ãšåäžæ¹æ³ã§
åæãè¡ãªããèç¹120â125âã å®æœäŸ 38 âïŒãšã³ãâïŒâãã«ãã«ãã«ïŒâïŒâããã
âïŒïŒïŒâãšãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšãšã³ãâïŒâãã«ããã«ã¢ãã³ã®åã¢ã«éã
çšãã次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœ
äŸ21ãšåäžæ¹æ³ã«ããåæãè¡ãªããèç¹130â
131âã å®æœäŸ 39 âïŒãã«ãã«ãã³âïŒâã€ã«ïŒâïŒâãããâ
ïŒïŒïŒâãšãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšãã«ãã«ãã³âïŒâã€ã«ã¢ãã³ã®åã¢ã«éã
çšãã次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯å®æœ
äŸ21ãšåäžæ¹æ³ã§åæãè¡ãªããããèç¹128â
132âã å®æœäŸ 40 âãããµã¡ãã¬ã³ã€ããâïŒâãããâïŒïŒ
ïŒâãšãã³ãžã¢ãã³ã®åæã ïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâããããšã
ã³ãšïŒ®âã¢ããâãããµã¡ãã¬ã³ã€ãã³ã®åã¢ã«
éãçšãã次ãã§ã¢ã³ã¢ãã¢ã飜åããã以å€ã¯
å®æœäŸ21ãšåäžæ¹æ³ã§åæãè¡ãªããããèç¹
127â131âã æ¬çºæã«é¢ããŠç¹å®ã®å ·äœçå®æœæ æ§ãåç §ã
ãªãã詳ãã説æããããããæ¬çºæç¯å²å ã§åœ
æ¥è ãçš®ã ã®å€åœ¢å®æœåã³ä¿®æ£ãè©Šã¿ãããšã¯å®¹
æã«ãããããšãæçœã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒïŒïŒïŒ ãåŒäžãã¯ãããªãžããïŒâã¡ãã«ãããªãž
ããïŒïŒââãšãã«ãããªãžãã«ïŒã¢ãããïŒ
âïŒïŒâããããã·ãšãã«ïŒâïŒâããã©ãžããïŒ
âãã³ãžã«ãããªãžããïŒâãã³ãžã«ããã©ãž
ãããšãã¬ã³ã€ãããã·ã¯ããããã¬ã³ã€ããã
ã·ã¯ãããã·ã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãž
ãšãã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãžãšãã«â
ïŒâã¡ãã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãžãšã
ã«âïŒâãšãã«ã¢ããããããµã¡ãã¬ã³ã€ããã
ïŒïŒ®âãããµã¡ãã¬ã³ã€ããïŒã¢ãããã·ã¯ãã
ããã«ã¢ãããã·ã¯ããã³ãã«ã¢ããããããªãž
ããã¢ã«ããªãããšã³ãâïŒâãã«ãã«ãã«ã¢ã
ãåã¯ãã«ãã«ãã³âïŒâã€ã«ã¢ããåºãè¡šã
ããã ã§ç€ºãããååç©åã³ãããã®è¬ç©çã«èš±å®¹ãã
ãå¡©ã ïŒ è¬ç©çã«èš±å®¹ãåŸãå¡©ã¯ãå¡©åæ°ŽçŽ é žå¡©ãè
åæ°ŽçŽ é žå¡©ããšãŠåæ°ŽçŽ é žå¡©ããªã³é žå¡©ãç¡«é ž
å¡©ããã¬ã€ã³é žå¡©ããããé žå¡©ãé ¢é žå¡©ãã¯ãšã³
é žå¡©ããããé žå¡©ããã¯ãé žå¡©ãå®æ¯éŠé žå¡©ãé
ç³é žå¡©ãããã«é žå¡©ããã³ãã«é žå¡©ãã¢ã¹ã³ã«ã
ã³é žå¡©ãã¡ãã«ã¹ã«ãã³é žå¡©ãåã¯ãšãã«ã¹ã«ã
ã³é žå¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®å¡©ã ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡
ãã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒâ
ãããªãžãâïŒâããããšãã³ã§ããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡
ãã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒâ
ïŒïŒâã¡ãã«ãããªãžãïŒâïŒâããããšãã³ã§ã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒ ïŒ®âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ãã«ã
ãã«ããªã«ïŒããªããšãã«ãâNâ²âïŒïŒ®âãšãã«
ãããªãžãã«ïŒâïŒâãããâïŒïŒïŒâãšãã³ãž
ã¢ãã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åå
ç©ã ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡
ãã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒâ
ãïŒâïŒïŒâããããã·ãšãã«ïŒâïŒâããã©ãžãã
âïŒâããããšãã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
èšèŒã®ååç©ã ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡
ãã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒâ
ïŒïŒâãã³ãžã«ãããªãžãïŒâïŒâããããšãã³ã§
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡
ãã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒâ
ïŒïŒâãã³ãžã«âïŒâããã©ãžãïŒâïŒâããããš
ãã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡
ãã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒâ
ãšãã¬ã³ã€ããâïŒâããããšãã³ã§ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒ
ã¡ãã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒ
âã·ã¯ããããã¬ã³ã€ããâïŒâããããšãã³ã§
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãâNâ²âã·ã¯ãã
ãã·ã«âïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³ã§
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãâNâ²âïŒïŒïŒïŒ
âã·ã¯ããããµãžãšãã«ïŒâïŒâãããâïŒïŒïŒ
âãšãã³ãžã¢ãã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èš
èŒã®ååç©ã ïŒïŒ âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãâNâ²âïŒïŒïŒïŒ
âã·ã¯ããããµãžãšãã«âïŒâã¡ãã«ïŒâïŒâã
ããâïŒïŒïŒâãšãã³ãžã¢ãã³ã§ããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãâNâ²âïŒïŒïŒïŒ
âã·ã¯ããããµãžãšãã«âïŒâãšãã«ïŒâïŒâã
ããâïŒïŒïŒâãšãã³ãžã¢ãã³ã§ããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒ
ã¡ãã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒ
âãããµã¡ãã¬ã³ã€ããâïŒâããããšãã³ã§ã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãâNâ²âãããµã¡
ãã¬ã³ã€ããâïŒâãããâïŒïŒïŒâãšãã³ãžã¢
ãã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãâNâ²âã·ã¯ãã
ããã«âïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³ã§
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãâNâ²âã·ã¯ãã
ã³ãã«âïŒâãããâïŒïŒïŒâãšãã³ãžã¢ãã³ã§
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒ
ã¡ãã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒ
âãããªãžãâïŒâããããšãã³ã§ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ ïŒââãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒ
ã¡ãã«ããã«ããªã«ïŒããªããšãã«ãã¢ããâïŒ
âã¢ã«ããªãâïŒâããããšãã³ã§ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒïŒ âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãâNâ²âïŒãšã³ã
ãã«ãã«ãã«ïŒâïŒâãããâïŒïŒïŒâãšãã³ãž
ã¢ãã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åå
ç©ã ïŒïŒ âãïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ïŒããªããšãã«ãâNâ²âïŒãã«ã
ã«ãã³âïŒâã€ã«ïŒâïŒâãããâïŒïŒïŒâãšã
ã³ãžã¢ãã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®å
åç©ã ïŒïŒ è¬ç©çã«èš±å®¹ãããå¡©ã§ããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé ä¹è³ç¬¬ïŒïŒé èšèŒã®ååç©ã ïŒïŒ åŒïŒïŒïŒ ã§ç€ºãããïŒâããïŒâãïŒãžã¡ãã«ã¢ããïŒã¡ã
ã«ããã«ããªã«ãããªããšãã«ã¡ãã«ã¹ã«ãã€ã
ãšã åŒïŒïŒïŒ ãåŒäžãã¯ãããªãžããïŒâã¡ãã«ãããªãž
ããïŒïŒââãšãã«ãããªãžãã«ïŒã¢ãããïŒ
âïŒïŒâããããã·ãšãã«ïŒâïŒâããã©ãžããïŒ
âãã³ãžã«ãããªãžããïŒâãã³ãžã«ããã©ãž
ãããšãã¬ã³ã€ãããã·ã¯ããããã¬ã³ã€ããã
ã·ã¯ãããã·ã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãž
ãšãã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãžãšãã«â
ïŒâã¡ãã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãžãšã
ã«âïŒâãšãã«ã¢ããããããµã¡ãã¬ã³ã€ããã
ïŒïŒ®âãããµã¡ãã¬ã³ã€ããïŒã¢ãããã·ã¯ãã
ããã«ã¢ããããããªãžããã¢ã«ããªãããšã³ã
âïŒâãã«ãã«ãã«ã¢ããåã¯ãã«ãã«ãã³âïŒ
âã€ã«ã¢ããåºãè¡šãããã ã§ç€ºãããååç©ãšã80âã§åå¿ãããããã
åŸãåŸãããååç©ãåé¢ããæŽã«å¿ èŠã«ããå¡©
åããããšãç¹åŸŽãšãããåŒïŒïŒïŒ ãåŒäžãã¯åè¿°ã®æå³ãæãããã ã§ç€ºãããååç©åã³ãããã®è¬ç©çã«èš±å®¹ãåŸ
ãå¡©ã®è£œé æ¹æ³ã ïŒïŒ åŒïŒïŒã®ååç©ã®éå°éãçšããåå¿æ··
åç©ã80âã§ïŒæéç¶æããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
ïŒé èšèŒã®è£œé æ¹æ³ã ïŒïŒ åŒïŒïŒã®ååç©ã¯ãåŒïŒïŒïŒ ã§ç€ºãããïŒïŒïŒâãã¹ïŒã¡ãã«ããªïŒâïŒâã
ãããšãã¬ã³ãåŒïŒïŒïŒRHïŒïŒ²ã¯åè¿°ã®æå³ã
æããïŒã§ç€ºãããååç©ãšåå¿ããã次ãã§ã¢
ã³ã¢ãã¢ãšåå¿ãããŠåŸããããã®ã§ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒïŒé åã¯ç¬¬ïŒïŒé èšèŒã®è£œé æ¹æ³ã ïŒïŒ 掻æ§èŠçŽ ãšããŠæå¹éã®åŒïŒïŒ ãåŒäžãã¯ãããªãžããïŒâã¡ãã«ãããªãž
ããïŒïŒââãšãã«ãããªãžãã«ïŒã¢ãããïŒ
âïŒïŒâããããã·ãšãã«ïŒâïŒâããã©ãžããïŒ
âãã³ãžã«ãããªãžããïŒâãã³ãžã«ããã©ãž
ãããšãã¬ã³ã€ãããã·ã¯ããããã¬ã³ã€ããã
ã·ã¯ãããã·ã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãž
ãšãã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãžãšãã«â
ïŒâã¡ãã«ã¢ãããïŒïŒïŒâã·ã¯ããããµãžãšã
ã«âïŒâãšãã«ã¢ããããããµã¡ãã¬ã³ã€ããã
ïŒïŒ®âãããµã¡ãã¬ã³ã€ããïŒã¢ãããã·ã¯ãã
ããã«ã¢ãããã·ã¯ããã³ãã«ã¢ããããããªãž
ããã¢ã«ããªãããšã³ãâïŒâãã«ãã«ãã«ã¢ã
ãåã¯ãã«ãã«ãã³âïŒâã€ã«ã¢ããåºãè¡šã
ããã ã§ç€ºãããååç©åã³ãããã®è¬ç©çã«èš±å®¹ãã
ãå¡©ã®ïŒçš®ä»¥äžã®ååç©ãæå¹æåãšããŠå«æã
ãããšãç¹åŸŽãšãã朰çæ²»çå€ã ïŒïŒ çµå£åã¯æ³šå°æäžã«é©ããç¹èš±è«æ±ã®ç¯å²
第ïŒïŒé èšèŒã®æœ°çæ²»çå€ã ïŒïŒ é å€åœ¢ç¶ãæããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé
èšèŒã®æœ°çæ²»çå€ã ïŒïŒ 掻æ§èŠçŽ ãæç¶æ æ§ã§æŸåºãããé å€åœ¢ç¶
ãããŠããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æœ°çæ²»
çå€ã ïŒïŒ åé å€ã掻æ§èŠçŽ ã20ã500mgå«æããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æœ°çæ²»çå€ã ïŒïŒ äžåæäžåè¢è©°ã調åå€åã¯å³æ調åå¯èœ
ãªã·ãããåã¯æžæ¿æ¶²ã®åœ¢æ ããšãç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒïŒé èšèŒã®æœ°çæ²»çå€ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT20954/82A IT1190793B (it) | 1982-04-27 | 1982-04-27 | Composti attivi nel trattamento dell'ulcera e sintomi allergici della pelle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6081177A JPS6081177A (ja) | 1985-05-09 |
| JPH0429671B2 true JPH0429671B2 (ja) | 1992-05-19 |
Family
ID=11174566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58183243A Granted JPS6081177A (ja) | 1982-04-27 | 1983-10-03 | 朰çã®æ²»çã«æŽ»æ§ãæããååç©ïŒãã®è£œæ³åã³ãããçšãã朰çæ²»çå€ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4613596A (ja) |
| EP (1) | EP0092647B1 (ja) |
| JP (1) | JPS6081177A (ja) |
| AT (1) | ATE24904T1 (ja) |
| AU (1) | AU563738B2 (ja) |
| CA (1) | CA1223257A (ja) |
| DE (1) | DE3369135D1 (ja) |
| IT (1) | IT1190793B (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1196133B (it) * | 1984-06-06 | 1988-11-10 | Ausonia Farma Srl | Derivati furanici con attivita' antiulcera |
| IT1180185B (it) * | 1984-06-12 | 1987-09-23 | Magis Farmaceutici | Derivato della ranitidina utile nel trattamento dell'ulcera |
| US4707550A (en) * | 1986-04-28 | 1987-11-17 | Ortho Pharmaceutical Corporation | N-(substituted thienyl)-N'-(substituted piperazinyl)-ureas |
| ATE98955T1 (de) * | 1987-08-01 | 1994-01-15 | Takeda Chemical Industries Ltd | Alpha-ungesaettigte amine, ihre herstellung und verwendung. |
| GB9009437D0 (en) * | 1990-04-26 | 1990-06-20 | Glaxo Group Ltd | Chemical compounds |
| KR970703301A (ko) * | 1994-05-18 | 1997-07-03 | ìŒì€ë€ ì€ì¬ë¬Ž | ì ê· ëìë¯žë žë©ížëŠ¬ëŽ ì ë첎(novel diamincmethylidene derivative) |
| JP2000515554A (ja) | 1996-08-06 | 2000-11-21 | ã¹ãã¹ã¯ã©ã€ã³ã»ããŒãã£ã ã»ã³ãŒãã¬ã€ã·ã§ã³ | ïœâïŒå容äœã¢ã³ã¿ãŽãã¹ã |
| WO1998005317A1 (en) * | 1996-08-06 | 1998-02-12 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| AU5654399A (en) * | 1998-09-22 | 2000-04-10 | Ishihara Sangyo Kaisha Ltd. | Medical composition containing nitroetheneamine derivative or salt thereof as active constituent |
| KR100836547B1 (ko) * | 2002-01-11 | 2008-06-10 | ìêŸ ê°ë¶ìí€ê°ìŽì€ | ìë¯žë ž ììœì¬ ì ë첎 ëë í¬ì€í°ì° ì ë첎 ë° ìŽë€ìíšì íë ììœ ì¡°ì±ë¬Œ |
| NZ549162A (en) | 2004-02-24 | 2009-12-24 | Sankyo Co | Amino-pyrrol alcohol compounds |
| EP4196793A1 (en) | 2020-08-11 | 2023-06-21 | Université de Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4233302A (en) * | 1977-12-23 | 1980-11-11 | Glaxo Group Limited | Amine derivatives and pharmaceutical compositions containing them |
| US4287346A (en) * | 1979-02-16 | 1981-09-01 | Eisai Co., Ltd. | Cyanoguanidine derivatives |
| EP0057981A3 (en) * | 1981-02-09 | 1982-08-25 | Beecham Group Plc | Aromatic compounds, processes for their preparation and their use |
-
1982
- 1982-04-27 IT IT20954/82A patent/IT1190793B/it active
-
1983
- 1983-02-03 DE DE8383100992T patent/DE3369135D1/de not_active Expired
- 1983-02-03 AT AT83100992T patent/ATE24904T1/de not_active IP Right Cessation
- 1983-02-03 EP EP83100992A patent/EP0092647B1/en not_active Expired
- 1983-09-29 AU AU19760/83A patent/AU563738B2/en not_active Ceased
- 1983-10-03 JP JP58183243A patent/JPS6081177A/ja active Granted
- 1983-10-06 CA CA000438490A patent/CA1223257A/en not_active Expired
-
1985
- 1985-12-16 US US06/808,375 patent/US4613596A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IT8220954A0 (it) | 1982-04-27 |
| JPS6081177A (ja) | 1985-05-09 |
| EP0092647A1 (en) | 1983-11-02 |
| IT1190793B (it) | 1988-02-24 |
| CA1223257A (en) | 1987-06-23 |
| AU563738B2 (en) | 1987-07-23 |
| DE3369135D1 (en) | 1987-02-19 |
| US4613596A (en) | 1986-09-23 |
| EP0092647B1 (en) | 1987-01-14 |
| AU1976083A (en) | 1985-04-04 |
| ATE24904T1 (de) | 1987-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6156231B2 (ja) | ||
| JPH0114231B2 (ja) | ||
| IE53274B1 (en) | Chemical compounds derived from cyclobutene | |
| JPS5840956B2 (ja) | ã¢ããã¢ã«ãã«ãã©ã³èªå°äœããã®è£œæ³ããã³ãããå«æããå»è¬çµæç© | |
| NZ190623A (en) | Substituted 2-aminothiazoles and pharmaceutical compositions containing them | |
| JPH0429671B2 (ja) | ||
| JPS5946221B2 (ja) | è€çŽ ç°ååç©ã®è£œæ³ | |
| US3639477A (en) | Novel propoxyguanidine compounds and means of producing the same | |
| HU197842B (en) | Process for producing pharmaceutical compositions comprising 2-alkoxy-n-(1-azabicyclo/2.2.2/oct-3-yl)-benzamide derivatives | |
| US3742023A (en) | Novel 1-substituted phenoxy-2-hydroxy-3-isopropylamino-propanes | |
| JPS6242905B2 (ja) | ||
| JPS63310872A (ja) | ããŒããã³âβâããããã·ã©ãŒãŒæå¶å€ | |
| JPS6340784B2 (ja) | ||
| JPH0338269B2 (ja) | ||
| US3459767A (en) | Aminomethylindoles | |
| JPH02235868A (ja) | ã°ã¢ããžã³èªå°äœ | |
| US4515806A (en) | Furan derivatives and addition salts thereof pharmaceutical compositions and the therapeutical applications thereof | |
| Leonard et al. | 2-thenyl substituted diamines with antihistaminic activity | |
| US4593039A (en) | 1-aryloxy-3-(substituted aminoalkylamino)-2-propanols | |
| HU186164B (en) | Process for producing 1-bracket-3,4,5-trimethoxy-cinnamyl-bracket closed-4-bracket-amino-carbonyl-ethyl-bracket closed-substituted piperazine derivatives | |
| US3377245A (en) | Methods and compositions for treating hypertension | |
| JPH0357892B2 (ja) | ||
| JPS61158971A (ja) | ïŒâïŒã¢ãªã«ã¢ã«ãã«ãªãã·ã¡ãã«ïŒã¢ã«ããªãªã³èªå°äœããã®è£œé æ¹æ³ããã³ãããæåãšããè¬å€ | |
| US3943254A (en) | Beta-adrenergic antagonists | |
| JPH02264749A (ja) | ïŒïŒïŒïŒâãïŒïŒïŒïŒïŒïŒâããªã¡ããã·ïŒâãã³ãžã«ãªãã·ã¡ãã«ãâïŒâãã§ãã«âïŒïŒ®âãžã¡ãã«âïœâãããã«ã¢ãã³ |